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Chapter 1  
 
Introduction 
 
1 - MALIGNANT MESOTHELIOMA 
 
1.1. Aetiology of Malignant Mesothelioma  
Malignant Mesothelioma (MM) is a highly aggressive cancer arising from 
the mesothelial lining of the pleura, peritoneum and pericardium. Among 
these, Malignant Pleural Mesothelioma (MPM), that represents 
approximately 90% of cases, is the most common primary tumor of the 
pleura. MPM has a very poor prognosis; it typically spreads and invades 
locally, even though distant metastases to the contralateral lung, 
peritoneum, bone or liver can occur (1). 
The median survival is less than 12 months, depending on the stage of the 
disease at the time of diagnosis (2). MPM is associated with exposure to 
asbestos. Asbestos is the generic term for a group of naturally occurring, 
fibrous minerals with high tensile strength and resistance to heat, 
chemicals, and electricity. Six minerals, defined as "asbestos", are divided 
in two classes: the serpentine and the amphibole. Chrysotile (white 
asbestos), is the only one member of the serpentine class, is made up of 
curled fibers and accounts for approximately 95% of all asbestos used 
worldwide. The amphiboles’ group can be distinguished for its friable fibers 
and includes amosite (brown asbestos) and crocidolite (blue asbestos), 
extensively used in industries (3). 
Between the 1940s and 1979 in the United States and Europe, asbestos 
was widely used in the shipbuilding and construction industries thanks to its 
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fire-resistant properties (4). The incidence of asbestos-related diseases has 
been rising worldwide since 1970, due to the exposure during the past and 
it is predicted to increase further in coming decades, especially in 
developing countries where asbestos has not yet been banned. The mean 
latency period between the time of initial exposure and diagnosis is about 
30 years and ranges from 20 to 50 years; moreover, the disease latency 
has an inverse relationship with duration of exposure (5). 
The first hypothesis about a link between cancer and asbestos, was 
proposed by Wagner et al. (6) in 1870, who described crocidolite asbestos 
exposure in 33 cases of mesothelioma in South Africa’s North Western 
Cape, while further confirmations came during the following years when 
McDonald found a proportional mortality ratio for exposed subjects. 
Currently rates of MPM are rising and estimates indicate that the incidence 
of MPM will peak within the next 10-15 years. Although the use of asbestos 
has been banned in many countries around the world, production of and  
potentially hazardous exposure to asbestos is still present with locally high 
incidences. Today a new man-made material, carbon nanotubes (CNTs), 
has arisen as a concern; CNTs may display ´asbestos-like´ pathogenicity 
with mesothelioma induction potential (7). 
Exposure mapping within countries reveals high regional variability in 
incidence and mortality: for instance, in Italy, significant municipal clusters 
of disease have been identified close to asbestos industries, shipyards, oil 
refineries and petrochemical industries (8); similarly in the UK, the highest 
mesothelioma mortality rates were recorded in areas with a history of ship 
building, such as Barrow-in-Furness, Plymouth, Portsmouth, Tyneside and 
Southampton (9). The correlation between amphibole, asbestos exposure 
and MPM development is generally accepted and crocidolite is considered 
the most oncogenic type of asbestos. Even if the relative oncogenicity of 
the specific asbestos fibers type is controversial, the evidence has been 
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considered sufficient by the World Health Organization (WHO) to conclude 
that all types of asbestos cause cancer in humans (10).  
Asbestos fibers can be inhaled deeply and trapped in the lower lung where 
mechanically cause pleural irritation and induce an inflammatory response 
as consequence of repeated scratching of mesothelial surface. Moreover, 
phagocytosed fibers can initiate a cascade of events that includes 
activation of c-Myc and c-Jun oncogenes, binding with growth factor 
receptors (EGFRs) (11,12), or alternatively, mechanically interference with 
the mitotic process of the cell cycle by disrupting the mitotic spindle, with 
consequent chromosomal abnormalities and aneuploidy (13). Finally, 
another proposal is that asbestos can also induce reactive oxygen species 
(ROS) or reactive nitrogen species (RNS) (resulting in DNA damage), 
cytokines, growth factors -such as transforming growth factor-β (TGF-β)- as 
well as transcription factors -such as nuclear factor kappa B (NF-kB) and 
activator protein-1 (AP-1) (14, 15). 
 
1.2. MPM classification 
According to the WHO classification, based on the histological analysis of 
tissue obtained by biopsies, MPM is divided in three different classes: 
epithelioid, sarcomatoid and biphasic. 
 
Epithelioid 
Around 60% of all mesothelioma cases comprises mesothelial cells with 
epithelial-like shape arranged in tubulo-papillary or trabecular formations 
and represents the most common histotype characterized by a better 
prognosis (16).The most frequent patterns encountered are tubulopapillary, 
adenomatoid (microglandular) and sheet-like, while less common patterns 
include small cells, clear cells and deciduoid. In particular, the tubule 
papillary form shows varying combinations of tubules with connective tissue 
Chapter 1 – Introduction 
6 
 
cores and clefts. Most epithelioid mesotheliomas are singularly bland in 
appearance and mitoses are scarce; usually a pattern predominates but 
often-different ones are commonly found in the same tumor, as much as 
sheets and nets of cells are frequently seen in association with other 
patterns (17). The fibrous stroma of epitheloid mesotheliomas can show 
varying degrees of cellularity from hyalinised acellular to highly cellular, 
merging with sarcomatoid; furthermore, these tumors may be difficult to 
distinguish from biphasic mesotheliomas. 
 
Sarcomatoid  
Sarcomatoid histotype is associated with less differentiated and more 
aggressive tumors in which more than 90% of the cells assume a spindle 
morphology and are arranged in fascicles or sheets, showing many mitotic 
figures, necrosis, and cytological atypia. Cells frequently tend to be irregular 
rather than uniform and overlap one other: their pattern often looks like 
fibrosarcoma, but marked anaplasia and uncommon multinucleate tumor 
cells make it more similar to malignant fibrous histiocytoma (18). 
 
Biphasic  
The biphasic histotype contains both epithelioid and sarcomatoid patterns 
and each component should represent at least 10% of the tumor to warrant 
the term biphasic. Cells of the biphasic variety form groups rather than 
displaying a uniform mixture (19). 
 
1.3. Diagnosis, Staging and Prognosis 
Malignant mesotheliomas are not ordinarily graded.  
Patients with MPM commonly present with dyspnoea, chest wall pain and 
pleural effusion and diagnosis is often made at an advanced stage of the 
disease, so that in untreated patients median survival is less than one year. 
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Difficulty in diagnosing the disease, especially in its early stages, prevented 
the development of a generally accepted stage-related approach. In 
addition, MPM is a heterogeneous disease with a variable clinical course: 
the majority of patients (80%) are diagnosed in stage III/IV and these 
patients are not candidates for surgical cure (20). Thus, systemic therapy is 
the only treatment option for the majority of this kind of patients, but poor 
performance status and the low chemo and radio-sensitivity of the tumor 
result in a poor prognosis. For these reasons, advances in the 
understanding of the molecular biology of MPM is needed to establish 
diagnostic, therapeutic and prevention methods and allow the identification 
of promising new candidates for targeted treatments. 
Knowledge of the biological basis of MPM progression and response may 
facilitate a personalized treatment approach involving early identification of 
poor prognostic indicators that will reduce the heterogeneity of the clinical 
response (1, 18). 
One contributing factor for the diagnosis of malignant mesothelioma is the 
possibility to differentiate it from adenocarcinoma, a cancer originating in 
glandular tissue. The most important differential is metastatic or locally 
invasive (from lung or chest wall) tumor that covers the pleural surface, 
even if various localized tumors also exist in the pleura and some mimic 
mesothelioma microscopically. For this reason, knowledge of the 
distribution of tumor, whether obtained from radiographic studies, the 
operator’s description of the findings at thoracotomy or thoracoscopy, or 
from a resected specimen, is crucial to make a proper diagnosis. However, 
beyond the distinction between epithelioid and sarcomatoid forms, these 
histopathologic features do not always correlate well with prognosis (17). 
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Staging 
Several staging systems for mesothelioma have been used over the years, 
almost exclusively dealing with primary pleural mesothelioma. Peritoneal 
mesothelioma does not have its own staging system. The oldest staging 
system used for pleural mesothelioma is the Butchart system; it is still 
commonly used in some parts of the world (13). This method is based on a 
simple description of the extent of the disease without considering the 
histologic subtype: pleural contained (Stage I), chest wall or mediastinal 
invasion (Stage II), peritoneal or diaphragmatic penetration (Stage III), or 
distant metastases (Stage IV). Meanwhile, the Brigham system tries to 
define surgical resectability and lymph node involvement. Stage I disease is 
resectable without nodal spread while stage II is resectable with lymph 
node involvement. Stage III involves the chest wall, heart, diaphragm, or 
abdominal cavity, with or without lymph node involvement: stage III tumors 
are considered unresectable. Stage IV disease is distant metastases. This 
system is not utilized at present. The most practical and most commonly 
used system is the tumor-node-metastasis system developed by the 
International Mesothelioma Interest Group. This system is the currently 
accepted standard adopted by the American Joint Committee on Cancer 
(21, 22). Most patients present with advanced disease and are considered 
unresectable. 
 
Histopathology and Survival  
The prognosis for MPM is significantly affected by histopathologic variant. 
Most studies have found a clear survival benefit for patients with epithelioid 
subtype. A recently published study on 312 patients undergoing surgical 
therapy for MPM evaluated the effect of histology on survival (23). Patients 
with epithelioid subtype had the longest median survival of 15.3 months, 
and 1-year and 2-year survival of 63% and 32% respectively. Patients with 
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sarcomatoid subtype had a median survival of 5 months, and 1-year and 2-
year survival of 4% and 0%, respectively. The biphasic subtype had 
intermediate survival rates. Multiple other studies have demonstrated 
extremely poor survival for patients with sarcomatoid-type MPM regardless 
of medical or surgical therapy, and most centres do not offer surgery to 
these patients (24). 
 
1.4. Therapy 
Mesothelioma is difficult to treat because many people are not diagnosed 
until their disease is advanced and the decisions about treatments are 
based on different tasks: where the tumor arose and its stage, the grade of 
malignancy, its location, whether it is resectable or not, symptoms, general 
health conditions of the patient and age (25). Treatment options are limited 
and the results with conventional therapies have been rather disappointing 
to this date. Moreover, chemotherapy is the only evidence-based treatment 
for mesothelioma patients in good clinical condition, with an increase in 
median survival of only 2 months: so finding out new different approaches 
to afford this malignancy became necessary. 
Actually the therapy for mesothelioma is represented by surgery, 
radiotherapy, chemotherapy and the so-called “trimodality therapy” that 
consists in combination of chemotherapic drugs following surgery (26). 
 
1.4.1. Surgery and Radiation 
Surgery 
Surgery for mesothelioma could be done essentially for two reasons: to try 
to cure cancer or to relieve pain and other symptoms carried on by the 
tumor. The curative surgery is an option for patients who are living with 
good health conditions because the cancer has not spread a lot and it could 
be removed completely also because it is thought to be localized. However 
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sometimes surgeons are not able to remove all of the cancer, some cells 
remain and can grow normally, divide allowing the cancer to come back 
after surgery. Otherwise, palliative surgery may be an option if the tumor 
has already spread beyond where it started and complete removal is not 
possible, or if the patient is too ill for a more extensive operation (27). The 
type of surgery done depends mainly on the location of the tumor, the stage 
of the cancer, the subtype of mesothelioma and other factors, such as 
patient overall health, also because chemotherapy and radiation represent 
additional therapies that are used in combination with surgery.  
- Pleural mesothelioma surgery 
There are two types of surgical treatments that may be offered to patients 
with pleural mesothelioma: pleurectomy/decortication (P/D) 
and extrapleural pneumonectomy (EEP). People with early stage or 
localized (stage I) pleural mesothelioma are undergone to P/D with removal 
of both the parietal pleura and visceral pleura together with the tumor, while 
the lung is not removed. In more advanced stages, a P/D can also be done 
to help control fluid build-up in the chest, improving breathing and relieve 
symptoms, such as chest pain caused by the tumor. Patients in stage I or II, 
and some with stage III pleural mesothelioma are treated with extrapleural 
pneumonectomy (EPP), only if the tumor is considered operable, is 
localized and has not spread into the diaphragm – this typically occurs in 
patients with resectable mesothelioma of the epithelioid type whose cancer 
has not reached the lymph nodes(28). 
- Peritoneal mesothelioma surgery 
Surgery is not often possible for people with peritoneal mesothelioma, but 
in people who are elegible candidates for surgery this treatment is often 
done to help relieve symptoms or to remove the tumor from the abdomen 
wall and organs; unfortunately as with pleural mesothelioma, these tumors 
often have spread too far to allow a complete removal (29). Essentially, 
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people with peritoneal mesothelioma may have a peritonectomy, in which 
the membrane that lines the abdomen (peritoneum) is removed, sometimes 
involving also other structures; or an omentectomy, a surgery that removes 
the layer of fatty tissue that covers the contents of the abdomen, when 
mesothelioma spread beyond the peritoneum (30). 
 
Radiation 
The pattern of spread of malignant pleural mesothelioma (MPM) poses 
unique challenges to a radiation oncologist. At first, patients are treated with 
conventional radiation techniques, when radiotherapy administered as 
adjuvant therapy following extrapleural pneumonectomy (EPP) or 
pleurectomy/decortication (P/D) (31). Anyway, with conventional 
radiotherapy there may be radiation underdosing near regions that are 
blocked: this has the potential to lead to increased risk of local failure in 
approximately 10-15% of patients. More recently, complex intensity-
modulated radiation therapy (IMRT) techniques for the treatment of MPM 
have been explored, with early outcomes suggesting acceptable safety in 
appropriately selected patients. Multiple subsequent studies incorporated 
this technique into a multimodality approach combining chemotherapy, EPP 
and hemithoracic radiation (32). 
 
1.4.2. Chemotherapy and Multimodal Therapy  
Treatment modalities for MPM patients depend on age, performance status 
and disease stage at onset. It is now generally accepted that the future of 
cancer therapy lies in the combination of therapies with different 
mechanisms of action; actually the therapy for MPM is represented by 
surgery and radiotherapy, chemotherapy and the so-called “trimodality 
therapy” that consists in combination of chemotherapic drugs following 
surgery.  
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Chemotherapy 
A phase 3 trial of combined therapy using pemetrexed and cisplatin has 
shown major efficacy compared with cisplatin monotherapy and 
consequently, current approved first line therapy now include cisplatin and 
antifolate agent, such as pemetrexed or raltitrexed (33). 
Several other cytotoxic agents with definite activity in mesothelioma have 
recently been evaluated, including gemcitabine, vinorelbine and the 
antifolates pemetrexed and raltitrexed. Vinorelbine has been shown to have 
activity in a small phase II study; similar results have been achieved with 
vinflunine, a new semi-synthetic fluorinated vinca alkaloid. In contrast, 
taxanes, such as paclitaxel and docetaxel, showed very low or no activity. 
Platinum analogues, doxorubicin and some antimetabolites (methotrexate, 
raltitrexed, pemetrexed) have shown modest efficacy as single-agent. The 
combination of antifolates and cisplatin was proven to prolong survival over 
cisplatin alone in Phase III studies, while in other phase II studies, the 
combination of pemetrexed and gemcitabine was also effective as a first-
line chemotherapy for patients with MPM (34). 
Recently a study on 409 patients with MPM was conducted assigning them 
randomly to one of three treatments for 12 weeks: active symptom control 
(ASC) alone, ASC plus MVP (mitomycin vinblastine, and cisplatin), or ASC 
plus vinorelbine. The median survival was 7.6 months in the ASC alone 
group and 8.5 months in the ASC plus chemotherapy group. Considering 
that ASC group included treatments with steroids, analgesic drugs, 
bronchodilators or palliative radiotherapy, the addition of chemotherapy to 
ASC did not offered significant benefits in terms of the overall survival or 
quality of life (35). 
Chemotherapies consisting of doxorubicin, doxorubicin plus 
cyclophosphamide, oxaliplatin-raltitrexed or ZD 0473 (a platinum analogue) 
appeared ineffective. Some interesting response rates were noted with 
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pemetrexed alone, or the combination of carboplatin and pemetrexed and 
of cisplatin, irinotecan and mitomycine C, used as second line therapy (36). 
Weekly vinorelbine administration demonstrated useful clinical activity in 
the second-line treatment of MPM, resulting in a median overall survival of 
9.6 months. Gemcitabine and vinorelbinein pemetrexed-pretreated patients 
with MPM resulted in a 10.9-month median survival time. Moreover, 
retreatment of pemetrexed-pretreated patients appeared effective, with 1-
year survival rates of 71.0% for retreated patients versus 18.8% without 
retreatment.  
In patients receiving second-line chemotherapy after the phase 3 trial of 
pemetrexed plus cisplatin versus cisplatin alone, a positive impact on 
survival was evident. MPM patients receiving second-line therapy with 
pemetrexed exhibited significant anti-tumor activity, improved disease 
control rates, and longer progression-free survival than patients receiving 
the best supportive care alone, although survival was not improved (37, 
38). 
- Immunotherapy 
Immunotherapy is one of the more recent approaches to cancer therapy: it 
represents a new class of agents in the treatment of mesothelioma and it is 
based on the generally-accepted hypothesis that the immune system is the 
best tool humans have for fighting disease. This therapy is sometimes used 
by itself to treat cancer, but it is most often used in combination with 
traditional treatments like radiation, chemotherapy, and surgery in order to 
enhance their effects. One of the possible benefits of immunotherapy is that 
it has the potential not to be as toxic as radiation or chemotherapy, and less 
invasive than surgery. 
In the case of cancer, the immune system alone often fails to effectively 
fight the tumor; normally the immune system does not recognize tumor cells 
because they are derived from the body's own cells, so the body “thinks” of 
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the tumor as “self” and creates a phenomenon known as “tumor tolerance”. 
Otherwise the immune system may also recognize cancer cells, but the 
response is not strong enough to destroy the cancer (because the response 
is insufficient in amount, it does not occur in the right place in the body, or it 
does not send the right “immune cells”). Moreover, the tumor has the ability 
to defend itself and cancer cells may secrete substances that keep the 
immune system in check. Thus, in the case of cancer, the immune system 
needs something to afford it more efficiently (39). 
The purpose of cancer immunotherapy is to promote (activating or 
intensifying) the antitumor effects of the immune system of the patient; 
several approaches for immunotherapy have been developed over the 
years and some are in various stages of pre-clinical research.  
Immunotherapy can be divided in two main categories, passive and active 
immunotherapy. Passive immunotherapy uses in-vitro produced effectors 
that are able to influence tumor cell growth: the most common form is 
based on the monoclonal antibody therapy, which consists in humanized 
monoclonal antibodies targeting cells directly or indirectly, which efficacy 
may be often enhanced by linking a toxin (e.g., radionucleotides or 
anticancer drugs) (40).  Active immunotherapy approaches aim at inducing 
or boosting immune effector cells in vivo against tumor cells, through the 
administration of immune mediators capable of activating the immune 
system (i.e. cytokines capable recruiting specific immune cells for enhance 
antitumor immunity, as IL-2, IL-12, IL-15, TNF-α, GM-CSF). These 
cytokines can be used as single agent or in combination with other 
immunotherapeutic strategies (41). 
- Molecular-Targeted Therapy 
Epidermal growth factor receptor (EGFR), platelet-derived growth factor 
receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR), 
SRC, hepatocyte growth factor (HGF), transforming growth factor (TGF), 
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insulin like growth factor I receptor (IGF-1R), mammalian target of 
rapamycin (mTOR), histone deacetylases (HDAC), and the proteasome 
have been investigated and can be targeted in MPM treatment (42, 43). 
Several clinical studies have been conducted. Phase 2 clinical trials based 
on EGFR tyrosine kinase inhibitor (erlotinib and gefitinib) therapy have 
shown limited or no activity in MPM; probably, the lack of EGFR mutations 
that confer sensitivity to TK-inhibitors in NSCLC could also explain the 
resistance to EGFR tyrosine kinase inhibitors in this cancer. 
The phase 2 studies with the anti-EGFR monoclonal antibody, cetuximab, 
with platinum/pemetrexed are ongoing. In three phase 2 trials involving 
imatinib as a PDGFR inhibitor, no objective response was obtained; 
moreover, a combination of imatinib with gemcitabine, 
cisplatin/gemcitabine, or cisplatin/pemetrexed has also been investigated 
without good outcomes (44,45). Bevacizumab, a recombinant human anti-
VEGF monoclonal antibody that blocks the binding of VEGF to its 
receptors, is under evaluation in a double-blind, randomized phase II trial in 
combination with cisplatin and gemcitabine. 
Other novel agents under investigation include sorafenib, an inhibitor of 
VEGFR-2, PDGFR-b, and B-Raf tyrosine kinase; in a phase I trial, 
vorinostat, a histone deacetylase inhibitor, has produced objective 
responses in 20% of MPM patients, and a phase III double-blind, placebo-
controlled trial is under way (46). 
 
Multimodal Management of MPM 
Failure of single-modality treatments to increase survival in MPM patients 
has led to a variety of multimodality approaches.  
The typical curative surgical treatment is extrapleural pneumonectomy 
(EPP) that involves a total en-bloc resection of the lung, pleura, 
pericardium, and diaphragm, while pleurectomy/decortication (P/D) involves 
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resection of the parietal and visceral pleura, and pericardium. This 
cytoreductive surgery has been added to systemic and/or intrapleural 
chemotherapy and to external-beam or intraoperative RT, with the main aim 
of improving local control. Early studies of neoadjuvant chemotherapy 
followed by EPP and hemithoracic RT have been published, and 
confirmatory trials on patients are ongoing. 
Several studies applying gemcitabine and cisplatin as an induction 
chemotherapy in combination with EPP and radiation in a combined-
modality approach for resectable MPM have been also reported.  
Patients completing trimodality therapy displayed a median survival of 29.1 
months and a 2-year survival rate of 61.2%.  
Patients who underwent trimodality therapy involving EPP and adjuvant 
chemoradiotherapy displayed a median overall survival of 13– 23.9 months. 
It was concluded that selected patients with MPM may benefit from EPP, 
particularly when combined with induction or adjuvant chemotherapy and 
adjuvant radiotherapy.  Due to its toxicity, is difficult to administer EPP as 
adjuvant chemoradiotherapy; thus, a trimodality therapy consisting of 
induction chemotherapy and EPP followed by radiotherapy was preferred. 
Finally, surgery may remove macroscopic diseases and multimodality 
therapy with radiation and chemotherapy should be included to eradicate 
residual microscopic disease (47, 48). 
 
2 - AKT 
 
2.1. AKT Family: Isoforms and Roles 
AKT/PKB (Protein Kinase B) regulates many cellular functions such as cell 
growth and proliferation, cell survival, apoptosis, energy metabolism, 
migration and resistance to anticancer therapeutics (49). Despite the 
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growing amount of researches demonstrating the existence of isoform-
specific regulation, many papers still draw generalized conclusions about 
AKT functions without considering the unique function of each AKT isoform. 
AKT family consists of three isoforms, AKT1, AKT2 and AKT3 (also known 
as PKBα, PKBβ and PKBγ, respectively) (50). Although these three 
isoforms are encoded by separate genes, they share a common NH2-
terminal pleckstrin homology (PH) domain (of 110 amino acids), a catalytic 
(kinase) domain in the middle (of about 260 amino acids) separated by a 
hinge region of 39 amino acids (“Linker”) and a C-terminal regulatory 
domain (with an identity in amino sequence of about 80%), which contains 
an hydrophobic motif, characteristic of the cAMP-dependent protein kinase 
A/protein kinase G/protein C (AGC) superfamily of protein kinases (51). 
They are differentially expressed in various tissues: AKT1 is most abundant 
in brain, heart, and lung; AKT2 is predominantly expressed in skeletal 
muscle and embryonic brown fat, while AKT3 is mainly expressed in 
kidney, brain and embryonic heart, although it is also present in adipose 
tissue, mammal glands and lungs. 
AKT isoform-specific knockout mice suggest that different AKT kinases are 
not completely overlapping and that isoform-specific signaling contributes to 
the diversity of their biological function. 
- AKT1 knockout mice are smaller than littermate controls and show 
increased rates of apoptosis in some tissues, reflecting its role in cell 
survival (52). 
- AKT2 null mice develop type 2 diabetes and impaired glucose 
utilization, suggesting its importance in the insulin receptor-signaling 
pathway (53). 
- The precise role of AKT3 is less understood: AKT3 is a key 
modulator of several tumors like glioma, ovarian cancer and 
melanoma in which an increase of active this isoform promotes 
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tumorigenesis by decreasing apoptosis; moreover, mice lacking 
AKT3 show impaired brain development (54). 
 
2.2. PI3K/AKT/mTOR Pathway 
AKT activity is modulated downstream of phosphatidylinositol 3 (PI3) kinase 
via a multistep process that starts in response to various growth factors and 
cytokines such as plateled-derived growth factor receptor (PDGF-R), 
epidermal growth factor (EGF) and insulin-like growth factor1 (IGF-1). In the 
absence of growth factor stimulation in quiescent cells, all three isoforms of 
the AKT kinases are catalytically inactive (55). 
The PI3Ks constitute a family of intracellular lipid kinases that 
phosphorylate the 3’-hydroxyl group of phosphatidylinositols (PIs) and 
phosphoinositides. Based on structure and their specificity for substrates, 
PI3Ks are classified into three groups (classes I, II and III). 
Class I PI3Ks are the primary lipid kinases that generate PIP3 from PIP2, 
and are subdivided into two classes (a, activated by growth factor TK-
receptor, and b, activated by G protein-coupled receptors); class II binds 
clathrin and are while both (class II and III) use PI to generate PI-3-P (56). 
After ligand-induced activation of specific receptors, a phosphorylated Y 
residue on receptor serves as docking site for regulatory p85 sub-unity of 
PI3K that recruits p110 sub-unity to the complex. PI3K activated localizes to 
the cytoplasmic face of the plasma membrane, where it converts PIP2 
(phosphatidylinositol 4,5-bisphosphate) to PIP3 (phosphatidylinositol 3,4,5-
trisphosphate), which promotes membrane localization of molecules such 
as AKT and 3-phosphoinositide- dependent kinase 1 (PDK1) by binding to 
their PH domain. 
The C-terminal PH domain of PDK1 binds phospholipids, keeping it 
constitutively localized at the plasma membrane; upon GF stimulation AKT 
interacts with these phospholipids, causing its translocation to the inner 
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membrane, where PDK1 is located. The interaction of the AKT PH domain 
with 3’- phosphoinositides makes conformational changes in AKT with the 
exposure of its main phosphorylation sites, T308 and S473 (57). 
Direct homodimerization of the two PH domains between AKT and PDK1 
might phosphorylate Thr-308 in AKT, which stabilizes the activation loop in 
an active conformation and renders Ser473 phosphorylation by mTORC2 
(mammalian target of rapamycin complex 2), resulting in full activation of 
the kinase. However, other molecules, including integrin-linked kinase (ILK) 
and mitogen-activated protein kinase-activated protein kinase-2 (MAPK-
APK2), mTOR and AKT itself have also been described to phosphorylate 
Ser473 (58). Full activation of AKT is a multistep process that leads to AKT 
phosphorylation on two sites, Thr308 (for human AKT1) and Ser473 (for 
AKT1). 
In particular, to optimize the kinase activity of all AKT isoforms, the 
concomitant phosphorylation of threonine and serine residues is required: 
curiously, they are these two aminoacids are positioned in marginally 
different locations in the three isoforms. 
For instance, the most essential regulatory amino acid residues are 
threonine 308 and serine 473 in AKT1, whereas the amino acid residues 
are threonine 309 and serine 474 in AKT2, while in the case of AKT3, the 
regulatory residues are threonine 305 and serine 472 (59). 
AKT can be activated in a PI3K-independent manner: for example, agonists 
of the PKA pathway, such as cAMP elevating agents, can activate AKT: 
calcium binds to calmodulin, and the Ca2+/calmodulin complex activates 
the calcium/calmodulin dependent kinase kinase (CaMKK), which directly 
phosphorylates T-308. Finally, some non-kinase interactors such as 
Hsp90/Cdc37 (molecular chaperone and co-chaperone), Hsp27, Tcl1 (T-
cell leukemia family), Grb10 (growth factor receptor binding protein10), Ft1 
and many others can positively regulate AKT catalytic activity (60). 
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2.3. Downstream effectors of AKT 
AKT activation is primarily implicated in cell survival and cell growth through 
regulation of several substrates. Among these substrates there are:  
- regulators of cell survival or death, such as BAD, caspase-9, ASK1 
(apoptosis signal-regulating kinase 1), forkhead box O transcription 
factors (FoxOs), Bim1, FasL, inhibitor of nuclear factor-kB kinase 
(IKK-NFkB), and p53;  
- regulators of angiogenesis, such as mTOR and hypoxia-inducible 
factor-1 (HIF-1);  
- regulators of cell metabolism, such as glucose transporter 1 (Glut1), 
GSK3, and a Ras homologue enriched in brain (RheB). 
AKT also regulates cell growth acting on tuberous sclerosis complexes 1 
and 2 (TSC1/2), mTOR, elongation-initiation factor 4E binding protein-1 
(4E-BP1) and mTOR pathway; it also modulates cell cycle progression 
through direct actions on the p21 and p27 (CDK inhibitors) and indirect 
effects on the levels of cyclin D1 and p53 (61). 
 
2.4. Inactivation of AKT 
AKT cascade can be blocked by cellular inhibitors as the phosphatase and 
tensin homolog (PTEN) and INPP4B, which directly antagonize PI3K 
functions, dephosphorylating PIP3 and revoking its downstream events. 
PTEN has been also demonstrated to be one of the most commonly altered 
genes in human malignancies. In contrast, gain-of-function AKT mutations 
are uncommon, but frequently occur at residue 17, within the PH domain 
(E17K-Lys 17 alters the electrostatic interactions of the pocket and forms 
new hydrogen bonds with a phosphoinositide ligand). This mutation 
activates AKT leading its localization to the plasma membrane, stimulates 
downstream signaling, transforms cells and induces leukemia in mice, 
indicating  a direct role of AKT in cancer; moreover, the E17K mutation 
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does not change AKTs sensitivity to ATP-competitive inhibitors, but it 
modify change its sensitivity to the allosteric ones (62). 
Negative regulation of PI3K/AKT pathways is mainly accomplished by 
PTEN (phosphatase and tensin homologue deleted). It was originally 
identified as a tumor-suppressor gene and was found frequently mutated in 
a wide variety of solid tumors, including endometrial, breast, prostate 
carcinomas, and glioblastomas. As a dual lipid and protein phosphatase, 
the primary physiological target of PTEN is considered to be the PI3K/AKT 
pathway. 
PTEN specifically catalyses dephosphorylation of the 3-phosphate of the 
inositol ring in PIP3, resulting in the biphosphate product PIP2 and 
inhibition of AKT activity. Inactivating mutations or loss of PTEN expression 
leads to a permanent increase in the basal level of PI3K/AKT signaling, 
generally resulting in increased cell proliferation and resistance to 
apoptosis. Recently, a family of novel protein phosphatases, namely, 
PHLPP (PH domain and leucine-rich repeat protein phosphatase), have 
been identified as important regulators of AKT kinases and protein kinase C 
(PKC). Two isoforms, PHLPP1 and PHLPP2, directly dephosphorylate 
Ser473 and therefore inactivate AKT. It has been shown that PHLPP 
differentially terminates AKT signaling through particular regulation of AKT 
isoforms. PHLPP2 dephosphorylates AKT1 and AKT3, whereas PHLPP1 is 
specific for AKT2. PHLPP expression is commonly lost in cancer, including 
colon, breast, ovarian, Wilms tumors, and prostate cancer, while its co-
deletion, together with PTEN is strongly associated with metastatic prostate 
cancer, suggesting the role of PHLPP as a tumor suppressor (63). 
 
2.5. Post-translational Modifications of AKT 
A part phosphorylation other post-translational modifications has been 
described to modify AKT activity/stability. 
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AKT acetylation 
The level of protein acetylation is regulated by enzymes that increase or 
decrease acetylation. When the balance between these mechanisms is 
altered, it results in protein hyperacetylation or deacetylation. As 
phosphorylation, the reversible acetylation of cellular proteins plays an 
important role in cellular processes; whereas different amino acids (i.e., 
threonine, serine, and tyrosine) can be phosphorylated, acetylation occurs 
only on lysine residues (64, 65). 
Deacetylases are enzymes that remove acetyl groups: they can be divided 
in four classes based on their structural and functional similarities, and 
among these, the major family is represented by sirtuin enzymes, that 
consist in seven components designated as SIRT1 through SIRT7, 
exhibiting different tissue distributions and subcellular localizations. 
Activity of AKT requires tight control, as evidenced by the multiple means 
by which the protein is regulated: phosphorylation, ubiquitination and 
binding to phospholipids.  
Recently, Sundaresan et al. reported the regulation of AKT and PDK1 by 
reversible acetylation. Their work showed that p300 and pCAF acetylate 
AKT and PDK1, while SIRT1 deacetylates them. The acetylation regulated 
the ability of AKT to bind PIP3, offering a new sight of AKT regulation 
through reversible acetylation: AKT was acetylated in murine cells in a 
manner inversely related to its activation. The kinase was associated with 
the histone deacetylase SIRT1 and deacetylation enhanced its ability to be 
activated. In contrast, activation of AKT after growth factor stimulation was 
inhibited in cells lacking SIRT1 (66, 67); moreover, cells effects on cardiac 
hypertrophy in mice lacking or overexpressing SIRT1 were associated with 
altered regulation of AKT. Thus, acetylation of AKT (regulated by SIRT1) 
appears to be an important aspect of control of different biological activities 
of the enzyme (68). Another elegant work conducted by Ramakrishnan and 
Chapter 1 – Introduction 
23 
 
colleagues, focused the attention on SIRT2, the primary cytoplasmic sirtuin, 
to which it have been attributed tumor suppressor functions and a role in 
maintaining genome integrity and in programmed necrosis. There is 
substantial crosstalk between the insulin-PI3K-AKT-metabolic pathways 
and sirtuins: SIRT1 and SIRT2 can deacetylate and regulate the function of 
FoxO transcription factors, which are direct AKT targets. 
In particular, they showed that the main sirtuin that binds and regulates 
AKT activation in insulin-responsive cells is SIRT2 rather than SIRT1.  
While AKT associates with both SIRT1 and SIRT2 in cells with constitutive 
PI3K activation, it exclusively binds SIRT2 in cells with normal regulation of 
the PI3K-AKT pathway. The SIRT2-AKT binding is induced by glucose and 
nutrient deprivation and PI3K inhibition, while insulin treatment induces the 
dissociation of the complex.   
Finally, the study identifies SIRT2 as a new positive AKT regulator that 
potentiates insulin responsiveness in normal cells, while both SIRT1 and 
SIRT2 play a role in maintaining AKT activation in cancer cells with 
constitutive PI3K activation; all these observations lead to considerate that 
SIRT2 activators could be useful  in  the  treatment of obesity-associated 
metabolic syndrome and type-2 diabetes, while SIRT1/2 inhibitors may 
have therapeutic use in cancers with constitutive PI3K-AKT pathway 
activation (69). 
 
Ubiquitin-dependent AKT degradation 
The ubiquitin proteasome system (UPS) regulates many cellular functions 
such as cell cycle, growth and cell polarity, through degradation of some 
proteins. The UPS acts involving the sequential activation of three 
enzymes: ubiquitin activating enzymes (E1), ubiquitin-conjugating enzymes 
(E2), and ubiquitin ligases (E3), which determine the specificity of 
substrates; activation of E1, E2, and E3 results then in the conjugation of 
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ubiquitin to the lysine residues of target proteins, that are tagged with poly-
ubiquitin and degraded by the proteasome complex (70, 71, 72). 
It is demonstrated that E3 ligases are involved in AKT degradation by UPS: 
Kim et al. reported that mannitol-induced degradation of AKT can be 
blocked by IGF-1, while in other studies reported that deprivation of 
vascular endothelial growth factor (VEGF) or blockade of the VEGF 
cascade with the tyrosine kinase inhibitor PTK787/ZK222584 resulted in a 
specific decrease of AKT protein level and the subsequent cellular 
stimulation with VEGF rescued AKT stability in endothelial cells (73, 74). In 
addition, the mTOR inhibitor also neutralized the VEGF-protective effect in 
proteolysis-dependent reduction of AKT protein, suggesting that this 
signaling is involved in VEGF-protected AKT degradation (75). Moreover, 
mTORC2 is generally rapamycin insensitive, while the rapamycin-sensitive 
mTORC1 lies downstream of AKT;  other groups reported that selective 
AKT degradation by the UPS in dendrites is required for generating 
neuronal polarity under physiological conditions, and those findings indicate 
that local protein degradation of AKT mediated by the UPS is important in 
determining neuronal polarity (76). 
 
Caspase-mediated AKT cleavage 
Differently from the UPS mediated AKT degradation, the mechanism by 
which AKT protein is cleaved by caspases is not completely clear. As a 
critical survival factor downstream of the receptor protein tyrosine kinases, 
AKT-transmitted survival signals have protective effects against apoptosis 
induced by a variety of stimuli. AKT protein is degraded when cells undergo 
apoptosis. Rokudai et al described that after incubation with active 
caspase, AKT was cleaved at three sites to produce 40- and 44-kDa 
fragments (77). As expected, the loss of the C-terminal domain of the AKT 
protein reduced its kinase activity; overexpression of AKT fragment with 
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deletion of the N-terminal domain or deletion of the C-terminal domain 
increased cell sensitivity to apoptosis-inducing stimuli, indicating that 
caspase-dependent cleavage of anti-apoptotic AKT turns off survival 
signals and increases apoptotic cell death (78). In interleukin-3 (IL-3)-
dependent 32D cells, Xu et al discovered that cytokine withdrawal resulted 
in AKT degradation by caspases as well: in this study, the authors identified 
the Asp462 residue of AKT1 as the primary cleavage site for caspase-3. 
Mutation of this site (AKT1-D462N) prevented caspase cleavage. Similar to 
previews description of C-terminal deletion fragment, the AKT truncation 
mutant mimicking the caspase cleavage product lost its kinase activity, 
functioning as a dominant negative mutant and promoting cell death. These 
results showed that the balance between AKT and caspase activity controls 
cell survival in 32D cells: moreover, upon survival factor withdrawal, 
caspases are able to render AKT inactive, inhibiting AKT pathway to allow 
apoptosis to occur (79). 
 
SUMOylation and AKT 
SUMO (Small Ubiquitin-like modifier) conjugation or “SUMOylation” is a 
post-translational modification (PTM), transient and reversible, that consists 
in the attachment of SUMO to specific lysine residues of target proteins, 
mainly nuclear proteins. SUMOylation affects activity, structure and sub-
cellular localization of the target proteins, promotes radical changes and 
plays a critical role in various cellular processes, including transcription, 
DNA repair/replication and cell cycle progression. Moreover, SUMOylation 
is involved in human disease such as neurodegenerative disorders 
(associated with huntingtin, ataxin-1, tau, PARK-7 or alpha-synuclein) and 
has been associated with cancer development, due to its cancer-related 
targets such as p53, pRB and Mdm2 (82). 
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SUMO conjugation shows some similarities with the ubiquitin pathway: 
SUMO needs to be cleaved to expose the glycine-glycine (GG) motif in its 
c-terminal (and this is performed by SUMO-specific proteases); mature 
SUMO is activated by the heterodimer SAE I/SAE II(E1), than it is 
transferred to the Ubc9 (E2) and finally Ubc9 transfers SUMO to the lysine 
in the target protein. While no role in proteolytic targeting has been 
observed, recently, SUMOylation has been demonstrated to function as a 
secondary signal that mediates the ubiquitin-dependent degradation (83). 
During years, most of the studies about the regulation of AKT activity have 
been focused on its phosphorylation, and in a second moment, acetylation 
and ubiquitynation have been considered as regulatory modifications of this 
protein. Recently, Risso and colleagues described AKT as target protein of 
SUMOylation: in particular, SUMOylation occurs at Lys276 and Lys301 
within the kinase domain of AKT and both residues are crucial for SUMO 
modification. They also demonstrated that different post-translational 
modifications don’t overlap, in fact diminished sumoylation of AKT didn’t 
prevent its phosphorylation at T308 or S473, and inhibition of PI3K did not 
alter basal (or Ubc9-stimulated) SUMO conjugation (84). 
However, downstream activities of AKT are drastically impaired in the 
SUMO-deficient mutant, indicating that this PTM does not regulate the 
activation of the kinase, but it might regulate its interaction with downstream 
targets. Moreover, considering the role of AKT in the balancing between 
cell survival and apoptosis they demonstrated  that SUMO conjugation to 
AKT is not only relevant for cell cycle progression at the G1/S transition, but 
has relevance also for the production of different mRNA splice variants, 
associated with cell proliferation and survival (83). 
Finally, in another work, Li et al. found that this PTM influences AKT activity 
in cell proliferation and tumor development: they showed that diminishing 
Chapter 1 – Introduction 
27 
 
SUMO conjugation to the cancer-associated mutant AKT1 E17K reduces its 
oncogenic capacity (84). 
 
 
Heat shock proteins and AKT stability 
 
Molecular chaperones are a group of proteins involved in the maintenance 
of other “clients” proteins in folded and active conformations. The term is 
usually related to proteins that play a role in protein folding and refolding 
and derived from a large family of genes, originally known as heat shock 
protein (HSP) genes; within this family we can find HSPA (Hsp70-Hsc70), 
HSPB (small HSP),  HSPD (Hsp60), HSPC (Hsp90) and HSPH (large HSP) 
(86, 87). 
These proteins conduct the folding of much of the proteome, with the 
formation of proteins (or complexes) able to direct several functions in the 
cell. Some of these proteins are also expressed at high levels after 
proteotoxic stresses such as exposure to high temperatures, heavy metals, 
alcohols or chemical agents: thus, they are mostly recognized as heat 
shock proteins.  
As a result of different proteotoxic stresses levels of unfolded, aggregated 
and ubiquitinated proteins increase and cells respond to insults through 
abundant synthesis of HSPs. These proteins are also known to be involved 
in cell survival after stress in two way: both through direct chaperoning of 
misfolded proteins, as well as inhibition of programmed cell death. 
Moreover, alterations in molecular chaperones regulation are also 
associated with human diseases (88). 
Among molecule chaperones, Hsp90 is one of most important proteins for 
the cancer cell survival. It contains a unique nucleotide binding-domain at 
its amino terminal pocket that binds ATP and has ATP hydrolysing activity. 
Hsp90 forms the basis of a super-chaperone machine that promotes the 
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proper folding of client proteins so that they can respond to a stimulus or 
bind a ligand. ATP hydrolysis and ADP/ATP nucleotide exchange drive the 
cycling of the Hsp-90–based chaperone machine: in fact, the half-life of a 
client protein depends by the period that it remains in association with the 
complex Hsp-90/Hsp-70, because during this time, the client protein is 
susceptible to ubiquitination and delivery to the proteasome where it is 
degraded (89, 90, 91). Client proteins of Hsp90 consist in various key 
components of multiple signaling pathways active in cancer cells to 
maintain growth and/or survival, and among these, PI3K/AKT/mTOR (92, 
93). Hsp90 also stabilizes AKT and prevents AKT from PP2A-mediated 
inactivation. When cells are exposed to heat shock, AKT is activated: the 
heat shock-induced AKT activation is PI3K dependent, as blocking PI3K 
leads to rapid dephosphorylation of AKT and detachment of AKT from 
Hsp90. This event increases AKT sensitivity to dephosphorylation mediated 
by PPA and subsequent degradation (94). Moreover, blockade of the AKT-
HSP-90 complex formation by the specific inhibitor 17-AAG (a 
geldanamycin analogue that is undergoing clinical testing in malignant 
melanoma and breast and prostate cancers) induces AKT 
dephosphorylation and degradation. In addition, 17-AAG can block the 
intrinsic ATPase activity of Hsp90 and subsequently block the formation of 
a multi-chaperone complex, including the AKT-Hsp90 complex. However, it 
is not yet clear in which patho-physiological conditions the ubiquitin 
proteasome pathway will recycle or degrade Hsp90-bound AKT (95). 
 
2.6. AKT in cancers 
The AKT/PKB (protein kinase B) kinases, which include AKT1, AKT2, and 
AKT3, are known to play an important role as intermediates of signaling 
pathways that regulate cellular processes as proliferation, survival, glucose 
metabolism, genome stability and neo-vascularization. 
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When deregulated they can contribute in development of cancer: moreover, 
AKT has been found mutated or hyperactivated in various solid tumors and 
haematological malignancies, underlining its crucial role in cancer 
progression, where AKT activation correlates with advanced disease or 
poor prognosis. Some studies evidenced that approximately 40% of breast 
and ovarian cancers and more than 50% of prostate carcinomas had 
increased AKT1 activity, while in other studies, the activation of the AKT2 
kinase was observed in 30–40% of pancreatic and ovarian cancers. 
Further, elevated AKT3 activity has been reported in oestrogen receptor-
deficient breast cancer and androgen-insensitive prostate cancer cell lines, 
suggesting that also AKT3 may contribute to the aggressiveness of these 
carcinomas (96). 
 
2.6.1. AKT in malignant mesothelioma 
As in many other cancers, the PI3K/AKT pathway plays a critical role for the 
cell cycle progression in human MPM cells and it has been reported that 
inhibition of the PI3K activity leads to significant cell cycle arrest and 
suppression of proliferation of different MPM cell lines. 
Activation of AKT, as described by Altomare et al. was observed in 65% of 
MPM specimens but no frequent genetic alterations were found for PI3-
K/AKT activation in mesothelioma cells (97). 
Recently our lab has firstly described that mesothelioma cells express the 
two isoforms of AKT, AKT1 and AKT3, while they completely lack of AKT2. 
The role and the relevance of AKT kinases in MPM are described, but no 
data are available on AKT1/3 expression and function in this kind of tumor.  
The PI3K/AKT signaling pathway, aberrantly active and involved in MPM 
cell cycle progression and chemo-resistance, represents a novel good 
therapeutic target. Various studies have also demonstrated that growth of 
tumor cells with elevated AKT activity is more sensitive to targeted 
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disruption of AKT signaling; moreover, these evidences suggest that 
targeting AKT activity sensitizes MPM cells to conventional drugs such as 
cisplatin, and that sensitivity after AKT inhibition might be more effective in 
cells with an elevated AKT activity. In a work recently published by our 
group, AKT was investigated as a relevant target of perifosine; it has been 
described that perifosine inhibits both AKT1 and AKT3 phosphorylation and 
activation in cells growing exponentially in serum-containing medium and 
after growth factor stimulation (98). 
 
2.6.2. AKT in ovarian cancer 
The involvement of AKT in cancer was firstly described in 1992 when 
Cheng et al. showed the hyperactivation of AKT2 in ovarian cancer cell 
lines. Ovarian cancer is the fifth most common cause of death due to 
cancer in women; therapy is successful at first, but the recurrence of the 
disease makes the rate of survival low. In ovarian cancer, the 
PI3K/AKT/mTOR pathway is frequently mutated or amplified, underlining its 
role in progression, cell proliferation, migration and chemoresistance of the 
tumor (99). 
Different studies report the expression of AKT in ovarian cancer: in 
particular, AKT1 and AKT2 were found activated and/or over-expressed, 
while AKT3 was detected up-regulated in over 20% of primary ovarian 
tumors and involved in the regulation of the G2/M transition. 
Tang et al. reported that AKT1 is frequently activated in ovarian cancer, 
while AKT2 has been shown to be amplified and overexpressed in human 
ovarian carcinoma cell lines and primary ovarian tumors, as described by 
Bellacosa and colleagues. Moreover, amplification of AKT2 was particularly 
frequent in undifferentiated ovarian tumors, suggesting a correlation 
between AKT alterations and tumor aggressiveness (100). 
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The main biological functions of AKT activation are anti-apoptotic and pro-
proliferative in cancer cells; proliferation and invasion are also affected 
when AKT is directly targeted as well: silencing of AKT1 isoform reduces 
proliferation and invasion of OVCAR-3 cells, while targeting the AKT2 
isoform has been shown to increase the activation of apoptosis (101). 
 
2.6.3. AKT in prostate cancer 
The PI3K/AKT/mTOR pathway has a pivotal role in prostate cancer and is 
estimated to be up-regulated in 30-50% of the cases, often associated with 
PTEN loss. Furthermore, phospho-AKT levels were also significantly 
greater in high-grade prostate tumors if compared to low/intermediate grade 
tumors, as different studies showed (102). In fact, according to the Gleason 
score, a grading assigned to a prostate tumor with values between 2 and 
10, when lowest numbers indicate slow-growing tumor and the highest 
ones indicate an aggressive tumor, phospho-AKT was detected mostly in 
tumor samples with Gleason score ≥8 (103). Levels of phospho-AKT were 
significantly increased in cancer cells relative to normal prostate epithelium 
and benign prostatic hyperplasia. In normal tissue AKT isoforms are 
present in different percentage, with the prevalence of AKT2 and AKT3, 
while changes in expression and activation of AKT have been reported in 
prostate cancer. Recent studies showed that silencing of AKT2 led to an 
increasing of migration, allowing epithelial-mesenchymal transition (EMT); 
on the contrary, silencing of other two isoforms did not evolve in such 
consequences. Moreover, down-regulation of AKT1 and AKT2, but not 
AKT3, induced activation of cell surface β1-integrins and enhanced 
adhesion, migration and invasion; while silencing of AKT1 and AKT2 
resulted in increased focal adhesion size (104). 
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2.6.4. AKT in lung cancer 
Lung cancer is one of the most common human cancers and non-small cell 
lung cancer (NSCLC) represents around 80% of deaths caused by all 
primary lung cancers. Due to diagnosis at late stages of the disease and 
despite advances in surgery and other treatments, the 5-year rate of 
survival for patients with NSCLC is only 15%. The annual incidence 
worldwide is more than 1.3 million lung cancer cases, while more than 1.1 
million lung cancer deaths per year are estimated (105). Researches based 
on molecular cancer biology and biochemical alterations evidenced that 
deregulation of some pathways involved in cellular proliferation and survival 
are responsible for cancer progression and among these, a pivotal role is 
played by the phosphoinositide-3-kinase/protein kinase B (AKT) signaling 
pathway. 
NSCLC cells express all the three AKT isoforms; in accordance with results 
published by different groups, there is a prevalence of AKT1 activation in all 
NSCLC subtypes. Regarding AKT1 and AKT3 activation, no significant 
difference between expression in tumor cores and control cores was 
observed, whereas PTEN and PI3K showed a significant difference in 
expression; in addition, high expression of PI3K was observed in 29% of all 
tumor core (106). Recently new findings studies have reported a lack of 
association between activated AKT and survival or clinic-pathological 
variables such as stage of disease and metastasis. In 102 NSCLC cases, 
Tang et al. found that patients with concomitant p-AKT Ser473 expression 
and loss of PTEN had a significantly reduced 5-year survival rate, while 
other research groups have reported the prevalence of phosphorylated AKT 
and its relevance to prognosis in NSCLC. Moreover, others studies 
observed high non-phosphorylated AKT2 expression in epithelial cells and 
considered it a positive prognosticator (107). 
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2.6.5. AKT in breast cancer 
Breast cancer is the most common malignancy among women, and it is the 
illness most frequently diagnosed in developed countries. Mutations in a 
number of genes are now known to cause susceptibility to breast cancer. In 
high-risk families, the most significant of these are the BRCA1 and BRCA2 
genes, while the human epidermal growth factor receptor 2 gene (HER2) is 
overexpressed and/or amplified in ∼15% of breast cancer patients and has 
been identified as a marker of poor prognosis (108). Other genes are 
involved in the genesis of breast cancer as well; these are tumor 
suppressor genes as p53 and PTEN: in particular, mutations in components 
of PI3K pathway and AKT hyper-activation are found in 70% of breast 
cancers. Studies in transgenic mice have shown that AKT promotes 
mammary tumor progression by increasing cell survival. The majority of the 
currently available in vivo data agree with the overall model whereby AKT1 
and AKT2 kinases play opposite roles in breast cancer migration, invasion 
and metastatic dissemination (events that ultimately determine the clinical 
outcome): as several studies reported, AKT1 functions as an inhibitor of 
migration and invasion in breast, while AKT2 acts in a positive manner 
(109). Moreover, AKT activation is associated with poor outcome in 
endocrine-treated breast cancer, whereas high levels of cytoplasmic AKT2 
are associated with an improved overall survival. AKT signaling pathway 
regulates also IKKε, an inducible kinase and is amplified and 
overexpressed in breast, and in particular AKT2, but not the AKT1 or AKT3 
isoform, is responsible for IKKε induction (110). 
 
2.6.6. AKT in skin cancer 
Malignant melanoma is a devastating tumor of the skin, with poor prognosis 
for patients (cause metastasis spread early) and resistant to all current 
treatments including chemo-, immuno-, or radiation therapy. In melanoma, 
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both the Ras/Raf/MEK/ERK (MAPK) and the PI3K/AKT (AKT) signaling 
pathways are constitutively activated and represent a crucial point for 
cancer development and progression; in particular, PTEN deletion leads to 
AKT activation that promote cell survival and can results in downstream 
loss of differentiation or senescence, through Raf-ERK cascades. 
Members of the PI3K and AKT3 signaling cascades have been implicated 
in initiation, progression, invasive, and drug resistance phenotypes of 
melanomas. Increased phospho-AKT expression in melanoma is 
associated with tumor progression and shorter survival: recently, has been 
also described that AKT3 in early melanocytic lesions can phosphorylate 
V600EBRAF reducing its activity and promoting proliferation to overcome the 
senescence block (111). 
Furthermore, the discovery of an AKT3 mutation in melanoma underlined 
the critical role of this isoform. Stahl et al (2004) described that AKT3 
protein, but not AKT1 or AKT2, was increased in melanoma cell lines when 
compared to normal melanocytes, while other studies reported that PTEN 
loss cooperates in increasing melanoma cell and non-transformed 
melanocytes capabilities of invasion and migration, by enhancing AKT2 
activity and through E-Cadherin down-regulation. Interestingly, targeting 
PTEN differentially regulates AKT3- mediated cell survival and AKT2-
mediated metastasis in melanomas (112). 
Expression of AKT3 has been detected elevated in cell lines derived from 
primary melanoma tumors at the radial and vertical stages of cell growth 
compared to normal melanocytes; on the contrary in the same samples, no 
significant changes were observed in the levels of AKT1 and AKT2, 
indicating that AKT3 expression is predominant in melanoma development. 
Although a central role of the AKT3 isoform in melanoma maturation is well 
established, this evidence still remain controversial: a recent report using 
biopsy of melanoma found AKT2 as a predominantly activated isoform in 
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melanomas, while a different study demonstrated that loss of PTEN 
promoted melanoma cell metastasis via activating AKT2 but not AKT1 or 
AKT3 (113, 114). 
 
2.6.7. AKT in thyroid cancer 
The Cowden’s syndrome, an autosomal dominant disorder characterized by 
the onset of various type of cancer affecting breast, colon, skin and thyroid, 
has been connected to the inactivation of the tumor suppressor PTEN, a 
phosphatase that regulates negatively the PI3K signaling, with the 
consequent constitutively activation of AKT. Although these observations, 
PTEN inactivation resulted to be sporadic in thyroid cancer, while AKT 
might be a central regulator of many thyroid oncogenes. 
In normal thyroid cells AKT activation is the major mediator of cell growth 
and inhibition of apoptosis; overexpression of an active form of AKT1 in 
thyroid cells results in serum-independent growth and leads to resistance to 
cell death, although it seems insufficient to transform the thyroid cells: this 
evidence suggests that additional signaling pathways are needed for 
developing thyroid cancer. Other recent study demonstrated that AKT 
signaling is enhanced in human thyroid cancer, in particular that AKT1 and 
AKT2 protein levels are increased in follicular thyroid cancer if compared 
with normal thyroid tissue as well as the level of phospho-AKT. Finally, 
among the isoforms, AKT2 results having an important role in the 
pathogenesis and/or progression of thyroid cancer (115). 
 
2.6.8. AKT in colon cancer 
Colorectal cancer (CRC) represents one of the most common malignancies 
in the world; it undergoes a multistage carcinogenesis pathway from 
adenomatous polyps to carcinoma and despite advances in chemotherapy, 
this tumor remains a major cause of death. Genetic events that lead to 
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neoplastic processes include alterations in tumor suppressor genes that in 
normal conditions regulate cell cycle progression, or somatic mutations in 
the TGFb receptor and the K-ras oncogene (116). 
Activation of AKT signaling and impaired expression of phosphatase and 
tensin homolog (PTEN) has been reported in 60-70% of human CRC and 
leads to inhibition of the pro-apoptotic GSK3b, with resulting increase in the 
levels of the anti-apoptotic beta catenin protein. AKT is up regulated in 57% 
of colon cancer, rate markedly higher than in other malignancies; moreover, 
AKT can act synergically with RAS and RAF cascades, both critical in 
colorectal carcinogenesis, and has been shown to impact also on WNT 
signaling, to regulate expression of the anti-apoptotic COX2 protein and to 
modulate cellular motility enhanced by prostaglandin E2. Although 
mutations in AKT genes are not frequently found in CRC, a somatic 
missense mutation of AKT1 (E17K) in the PH domain has been described 
and resulted in constitutive association of AKT1 with the plasma 
membrane, with its prolonged activation and mTOR deregulation. Finally, 
AKT proto-oncogene is overexpressed in cancer suggesting that its 
overexpression may be crucial in earliest stages of carcinogenesis process 
(117, 118). 
 
2.6.9. AKT in glioma 
Malignant glioma is the most common primary brain tumor in adults; it 
originates from the supportive cells of the brain (glial cells) and carries a 
poor prognosis. The median survival of patients with high-grade glioma 
(World Health Organization [WHO] grade III or IV) is 10-30 months despite 
multimodal treatment with surgery, radiation, and chemotherapy. 
Malignant gliomas develop because of the consequent accumulation of 
alterations in genes regulating cell proliferation, differentiation, and 
apoptosis. The amplification and mutation of tyrosine kinase receptors (i.e. 
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EGFR) activates several signaling pathways including the PI3K/AKT 
pathway that delivers major survival signals to human malignant glioma. 
AKT is activated in 70% of gliomas and is usually associated with PTEN 
mutations. Gliomas express all the AKT isoforms in different ratios; 
according to the WHO classification, the expression of AKT1 protein was 
not associated with the pathological glioma grade, while AKT2 expression 
was notably higher in tissues from grade III and IV than in normal tissues. 
On the contrary, AKT3 protein diminished with increasing glioma grades 
(119). 
Moreover, AKT3 was found down-regulated in malignant glioma cell lines 
overexpressing AKT2. In a recent study, Mure et al. observed the induction 
of apoptosis via the activation of caspase-9 and caspase-3 in glioma cell 
lines, after silencing of AKT2 or AKT3, while the combined knock-down of 
AKT2 and AKT3 effectively inhibited the growth of malignant cells, 
demonstrating the pivotal role of the two isoforms in the biology of this 
cancer (120). 
 
2.7. AKT Inhibitors 
Based on the evidence that AKT pathway has a pivotal role in various 
cellular functions and is one of the most frequently activated pathway in 
several type of cancers, the advent of targeted agents represents a new 
possibility to overcome the plateau achieved by current chemotherapic 
treatments. 
The three isoenzymes of AKT are not functionally identical, but their 
sequence is still similar to other kinases of the AGC family (>90% homology 
among AKT isoforms and >50% with PKA-α and PKC-α). Moreover, when 
considering the homology between ATP-binding site in AKT1 and AKT2 we 
reach almost the 100% (96% of homology with AKT2/3 and more than 70% 
with PKA-α / PKC-α). All these observations underline how the 
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development of specific inhibitors could represent an open challenge for 
researchers (121, 122). 
AKT inhibitors can be divided into four major classes based on their 
mechanisms of action and target regions. 
1) INHIBITORS OF THE KINASE DOMAIN (ATP-competitive 
inhibitors); it seems to be the most obvious target for therapeutics, 
but it is really the most difficult one to reach. Each kinase domain of 
AKT ends in a regulatory hydrophobic motif, but because of the high 
homology, the majority of them occupy entirely the ATP-binding site 
and acts as pan-AKT inhibitors. Numerous studies of AKT kinase 
inhibitors with reasonable selectivity and promising efficacy have 
been carried on. Luo et al., from a computational approach based on 
structure, generated a group of indazole-pyridine based pan-AKT 
inhibitors; among those, the most potent is A-443654 and targets the 
ATP-binding pocket with equal potency against AKT1, AKT2, or 
AKT3 within cells, but is more selective against AKT than other 
kinases in the AGC family (123).This class includes also compounds 
such as CCT128930 and GDC-0068 that inhibit respectively AKT2 
and AKT1 (the latter entered in Phase II trials) and the pan-AKT 
inhibitor GSK2110183 (afuresertib, itself in Phase II trials). 
GlaxoSmithKline created another AKT inhibitor, GSK690693 (AKT1: 
IC50= 2nM, AKT2: IC50= 13nM and AKT3: IC50= 9nM); it is 
aminofurazan-derived, ATP-competitive inhibitor. This molecule 
showed selective anti-proliferative effects in malignant cells and also 
downstream AKT phosphorylation events were reduced. In murine 
xenograft models, this agent led to a significant growth inhibition of 
tumors SKOV-3 cells (ovarian), LNCaP cells (prostate) and BT474 
cells (breast). Despite these encouraging preclinical data, clinical 
development of the agent was halted due to results from a phase I 
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trial testing an IV formulation of the agent, where studies on mice 
indicate that GSK690693 may inhibit glycogen synthesis and 
activate glycogenolysis, suggesting also that the inhibitor may induce 
peripheral insulin resistance (124, 125). 
 
2) INHIBITORS OF PIP3 BINDING-SITE; this class contains lipid-
based AKT inhibitors which act by preventing the generation of PIP3 
by PI3K. This mechanism is used by phosphatidylinositol analogues 
such as Calbiochem AKT Inhibitors I, II and III or other PI3K 
inhibitors such as PX-866. This class comprises Triciribine-
phosphate (TCN-P) that inhibits phosphorylation of AKT at Thr308 
and Ser473, as well as downstream p70S6K: it is highly selective for 
AKT and does not inhibit the activation of other kinases such as 
PI3K, PDK-1, PKC and PKA. In order to overcome the little 
specificity of inhibitors caused by the homology in ATP-binding 
pocket, targeting the PH domain to interfere with its binding to PIP3 
and membrane translocation became a good alternative to 
therapeutic compounds. AKT can be activated through binding to 3′ -
OH phosphorylated phosphatidylinositols via the PH domain. In 
order to block this interaction, a series of structurally modified 
phosphatidylinositol ether lipid analogues (PIAs) were drawn by 
computer-based modelling and synthesized. The best-characterized 
inhibitor of AKT is perifosine [octadecyl-(1,1-dimethyl-piperidinio-4-
yl)-phosphate], a synthetic novel alkylphospholipid (ALP) agents, 
which targets cell membranes: in vitro, perifosine interferes with the 
recruitment of AKT to the cell membrane and inhibits the growth of 
melanoma, lung, prostate, colon, and breast cancer cells in 
association with inhibition of AKT activity (126, 127). 
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Important, perifosine does not directly affect activity of PI3-K or 
PDK1; it induces p21Cip1, associated with G2/M phase cell 
accumulation, in head and neck squamous cell carcinoma cells. 
Most recently, combination treatment of human leukemia cells with 
perifosine and histone deacetylase inhibitors (HDACs) inhibited both 
AKT and MEK/ERK, induced ROS production and mitochondrial 
injury, and triggered apoptosis; moreover, perifosine was shown to 
sensitize tumor cells to conventional therapeutic antitumor agents 
and radiation(128, 129). 
 
3) ALLOSTERIC INHIBITORS OF AKT KINASE DOMAIN; MK-2206 is 
an investigational allosteric inhibitor of AKT that requires the PH 
domain of AKT for activity, but does not interact with the ATP binding 
pocket. Studies reported that MK-2206 is highly selective for AKT 
inhibition, has higher potency against recombinant human AKT1 and 
AKT2 isoforms than AKT3, has little off-target kinase activities, and 
is less vulnerable to feedback activation of AKT compared with ATP-
competitive inhibitors(130).In preclinical models, MK-2206 used in 
association with other targeted therapies showed synergy: for 
example, combination of MK-2206 with erlotinib in NSCLC cell lines 
and with lapatinib in breast cancer cell lines led to an important 
synergistic inhibition of growth. In addition, in xenograft studies 
utilizing mice bearing the A2780 ovarian cancer cell line, treatment 
with MK-2206 led to strong 60% growth inhibition together with 
sustained inhibition of all three AKT isoforms (occurring at 
nanomolar concentrations - AKT1=8nM, AKT2=12nM, AKT3=65nM) 
(131). 
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4) PSEUDO-SUBSTRATE INHIBITORS; this class includes 
compounds that bind the sites of catalytic domain in peptide/protein 
substrate. They are selective for many kinases and this 
characteristic derives from the much larger peptide-kinase contact 
region involved to discriminate various substrates. One of this 
compounds is AKTide-2T, that binds to the substrate binding site of 
AKT1 and inhibits its activity. Another hybrid peptide was recently 
generated this sequence and a sequence of the forkhead 
transcription factor FOXO3. Replacement of a putative 
phosphorylation site serine (Ser) in the sequence with an alanine 
(Ala) resulted in a further 10-fold improvement of potency. Fusion 
peptides were also constructed to allow cell uptake and 
demonstrated dose-dependent inhibition of GSK3b phosphorylation: 
although these peptides are selective inhibitors of AKT, their size 
makes them poor leads for consequent development (132). 
Another peptide-based approach is the development of a single-chain 
antibody (scFv) against AKT such as GST-antiAKT1-MTS. This antibody is 
the first genetically engineered scFv against AKT with inherent cell 
membrane translocation activity and detention of AKT inhibitory function 
associated with induction of apoptosis in vivo. Although the concept of 
peptide-based inhibitors seems promising, their development is currently 
hampered by their low bioavailability and stability in vivo (133). 
Apart from these, other molecules such as RX-0201, have it also yielded 
favorable results: RX-0201 represents an antisense oligonucleotide (AO) to 
mRNA encoding AKT1. In vitro, nanomolar concentrations of resulted in 
growth inhibition of various human cancer cell lines. When tested in two in 
vivo models (glioblastoma cells U251 or pancreatic cells MIA were 
implanted in nude mice), strong growth inhibition was also observed. In the 
radiation resistant H1299 NSCLC cell line, treatment with AKT1-AO 
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resulted in cytotoxicity. These encouraging studies led to further clinical 
development of the agent: a preliminary report of a Phase I trial with RX-
0201 included 17 patients with advanced solid tumors, in which the 
outcome was positive: moreover, phase II clinical trials are planned and a 
liposomal formulation is under development (134). Considering the wide 
quantity of new drugs discovered and under development, is necessary to 
define if they encounter the actual medical management; several current 
studies are assessing the safety of AKT inhibitors alone or in combination 
with both traditional chemical agents and other targeted therapies and 
these new findings could allow novel AKT inhibitors to complete existing 
treatments. 
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Chapter 2 
 
Outline of the thesis 
 
Malignant Mesothelioma (MM) is an asbestos-related highly aggressive 
cancer that arises from mesothelial cells. It is characterized by a long 
latency period, poor prognosis and high chemo-resistance; its incidence 
has been predicted to increase dramatically worldwide during the next two 
decades.  
The PI3K/AKT signaling pathway is one of the major pathways involved in 
carcinogenesis and tumor progression; it is aberrantly active in several 
human cancers and plays an important role in human malignant pleural 
mesothelioma (MPM). 
We firstly demonstrated that MPM cell lines express only two AKT isoforms 
(AKT1 and AKT3) and differently from lung adenocarcinoma derived cells 
they lack of AKT2; moreover, the two isoforms are expressed in different 
percentages in cells derived from tumors with different histotype. 
Based on these data, the first aim of this study was to better characterize 
the expression and function of the two AKT isoforms in MPM cells, and 
focus on their role in chemo-resistance.  
Our data show that treatment of MPM cells with the pan-AKT inhibitor 
MK2206 resulted in a significant reduction of cell viability and enhanced 
sensitivity to cisplatin, with an increase in apoptotic cell death. In addition, 
we compared the effect of silencing each AKT isoform in MSTO211-H cells 
to the inhibition of their kinase activity. Both AKT1 or -3 silencing reduced 
cell viability and increased apoptotic cell death in response to cisplatin 
treatment: this suggests that both isoforms play essential roles in cell 
survival, but probably they act through different mechanisms. 
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The roles of the different AKTs in cell migration and metastases have been 
described. Different and sometimes conflicting studies suggest either 
positive or negative regulatory roles of specific AKT isoforms.  
The MSTO211-H cell line is derived from a tumor with biphasic histotype, 
shows a spindle morphology and expresses high level of both AKT1 and -3 
isoforms. In this cell model we observed that AKT1 down-regulation caused 
a reversion versus a more epithelial phenotype when cell were cultured in 
monolayer, a reduction in spreading on Matrigel and inhibition of colony 
growth in soft agar. Conversely, AKT3 down-regulation did not influence 
these processes, neither modified cell morphology. 
These results led us to establish a primary role for the endogenous AKT1 
protein in affecting anchorage independent cell growth and underline the 
isoform-specific nature of this effect.  
AKT1 inhibition with MK2206 did not cause a change in cell morphology, 
while overexpression of AKT1 in the epithelioid  REN cells caused a 
change in their morphology towards a more spindle-shaped phenotype. 
These data suggest that these effects depend on the physical presence 
(and not on the activation status) of AKT1 and one can hypothesize that the 
drug-inhibited protein still interact with some partners or assemble into 
macromolecular complexes. 
As previously described in our laboratory, AKT in basal condition is in part 
phosphorylated and in part acetylated; upon SIRT1 inhibition, it becomes 
more acetylated and associates with different proteins, as shown by 
immunoprecipitation experiments. 
Based on this evidence, the last aim of my study was to explore the roles of 
these associated proteins and among them, we focused on HSC70, a 
chaperone protein constitutively expressed across tissues and cell types.  
Obtained data demonstrate that silencing of HSC70 leads to a strong 
reduction in cell viability and results in cell morphological changes, 
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associated with a decrease in E-Cadherin expression. We describe that 
AKT1 phosphorylation was affected by silencing of HSC70, while the total 
protein amount increased. EGF stimulus was not able to rescue AKT1 
activation. Furthermore, we observed that upon HSC70 silencing also 
EGFR phosphorylation and expression were compromised.      
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ABSTRACT 
The PI3K/AKT signaling pathway is aberrantly active and has an important 
biologic impact in human malignant pleural mesothelioma (MPM) 
progression and chemo-resistance.  
AKT family consists of three isoforms, AKT1, AKT2, and AKT3. Despite the 
growing amount of research demonstrating the existence of isoform-specific 
roles, many papers still draw generalized conclusions about AKT, without 
focusing on functional specificity of each isoform. Here we describe that 
MPM cells express increased AKT1 and AKT3 levels compared to non-
malignant mesothelial cells, with the highest expression in the biphasic 
subtypes.We show that both AKT1 and AKT3 play essential roles in the 
biphasic MPM cell survival and response to cisplatin treatment. Importantly, 
the knockdown of AKT1, but not of AKT3, results in a dramatic change in 
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cell-shape when cells are grown as monolayer in culture dishes or in a 
Matrigel matrix and in a near complete inhibition of colonies formation in 
soft agar. Our studies establish a role for the endogenous AKT1 protein in 
affecting anchorage independent MPM cell growth and highlight the is form-
specific nature of this effect. These data could be helpful for designing new 
effective therapeutic strategies. 
 
INTRODUCTION  
 
Human malignant pleural mesothelioma (MPM) is a rapidly lethal cancer 
associated with exposure to asbestos that is increasing in incidence 
worldwide [1, 2].  MPM is typically refractory to current treatment options 
using chemotherapy. Indirectly poly-chemotherapy has been demonstrated 
to increase overall survival against controls (from median of just 6 months 
to between just 9-12 months) [3, 4]. In a first line setting, pemetrexed in 
combination with cisplatin has been accepted as an almost universal 
standard [5]. In the second line setting, various chemotherapy agents are 
used, either as monotherapy or as part of polytherapy, but none has been 
validated and actually, no approved drugs reverse disease progression [6, 
7]. Therefore, there is a major unmet need for novel therapies for MPM. 
The PI3K/AKT signaling pathway, aberrantly active and with an important 
biologic impact in MPM progression and chemo-resistance, represents a 
novel good therapeutic target [8, 9]. AKT (also known as PKB) serine-
threonine kinases function as critical regulators of cell survival, proliferation, 
metabolism, and migration. Three isoforms of AKT have been identified in 
mammals: AKT1, AKT2 and AKT3 [11]. Although these three isoforms are 
encoded by separate genes, they share a conserved N-terminal pleckstrin 
homology (PH) domain, a central kinase domain, and a C-terminal 
regulatory domain, which contains the hydrophobic motif, a characteristic of 
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the cAMP-dependent protein kinase A/protein kinase G/protein C (AGC) 
superfamily of protein kinases. N-terminal PH domain, a catalytic domain in 
the middle, and a C-terminus. Findings from AKT isoform-specific knockout 
mice suggest that the functions of the different AKT kinases are not 
completely overlapping and that isoform-specific signaling contributes to the 
diversity of AKT activities. 
Thus, AKT1 knockout mice are smaller than littermate controls and show 
increased rates of apoptosis in some tissues, reflecting the role of AKT1 in 
cell survival. By contrast, AKT2 null mice develop type 2 diabetes and 
impaired glucose utilization, suggesting that AKT2 function is more specific 
for the insulin receptor signaling pathway. The precise role of AKT3 is less 
clear, however, mice lacking AKT3 display impaired brain development 
[12].  
Deregulation of AKT kinases is frequently associated with human diseases 
such as cancer [13]. All AKT isoforms possess in vitro transformational 
ability [14]; however, there may be isoform-specific functions in tumor cells 
where amplification or mutations have been detected [15].  
Despite the growing amount of research demonstrating the existence of 
isoform-specific regulation, many papers still draw generalized conclusions 
about AKT function in cancer cells without considering the unique function 
of each AKT isoform.  
Recently, our group published that MPM derived cell lines express both 
AKT1 and -3 isoforms but, differently from lung adenocarcinoma cells, not 
AKT2 [16].  
Here, we better define the relevance of AKT1 and -3 expression and 
activation in MPM cells.  
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MATERIALS AND METHODS  
 
Reagents and antibodies 
The pan-AKT and phospho-AKT1, -2, -3(pSer473) polyclonal antibodies 
and the monoclonal antibodies specific for PARP1 and α-tubulin were from 
Santa Cruz Biotechnology (Santa Cruz, CA). The monoclonal antibodies 
specific for AKT1 and AKT3 were from Rockland Immunochemicals Inc. 
(Gilbertsville, PA). 
Anti mouse and anti rabbit IgG peroxidase conjugated antibodies and 
chemical reagents were from Sigma-Aldrich (St Louis, MO). ECL was from 
Amersham Pharmacia Biotech (Uppsala, Sweden). Nitrocellulose 
membranes and protein assay kit were from Bio-Rad (Hercules, CA). 
Culture media, sera, antibiotics and LipofectAMINE transfection reagent 
were from Invitrogen (Carlsbad, CA).  
 
Cell cultures and transfection    
The epithelioid MPM derived REN cell line was isolated, characterized and 
kindly provided by Dr. S.M.Albelda (University of Pennsylvania, 
Philadelphia; PA, USA). The MM98 cell line derived from pleural effusions 
of patients with epithelioid MPM and the MESO-1 biphasic cell line were 
isolated, characterized and stabilized in culture [17,  18].The H2596 cell line 
was produced by Dr. H.I. Pass from surgical specimens derived from 
patients with resected sarcomatoid MPM [19]. The biphasic MSTO-211H 
and the mesothelial MET5A cell lines were obtained from the Istituto 
Scientifico Tumori (IST) Cell-bank, Genoa, Italy. Cells were cultured in 
standard conditions. Mycoplasma infection was excluded by the use of 
Mycoplasma Plus TM PCR Primer Set kit from Stratagene (La Jolla, CA). 
Cells grown to 80% confluence in tissue culture dishes were transiently 
transfected using LipofectAMINE reagent as described by the 
Chapter 3 – Article 
63 
 
manufacturer. Gene silencing was achieved using Akt1 or Akt3 -specific 
siRNAs by QIAGEN (Hilden, Germany). As a control was used QIAGEN 
non specific siRNA. HA-Akt expression vector was kindly provided by Dr. P. 
Defilippi (University of Turin, Italy). 
 
Cell cultures in a Matrigel matrix 
Briefly, 10×103 cells suspended in 50 μl of cell culture medium were seeded 
onto solidified Matrigel (BD-Biosciences, NJ) in 24-well plates. After 
incubation at 37°C, cells adhered to the surface of the gel and spread to 
form networks. These were observed under an inverted microscope and 
photographed live. The experiments were done in triplicate and repeated in 
independent conditions.  
 
Assay for anchorage-independent cell growth 
Anchorage-independent growth was determined using a modification of 
previously described methods [20]. Briefly, a base layer of 0.6%agar in 
complete medium was plated in six-well plates and allowed to solidify. Next, 
wells were overlaid with 5x103 cells per well in a 0.3% agar. The plates 
were incubated at 37°C, 5% CO2 for 15 days and checked every 2 days for 
colony formation. At day 7, individual colonies (defined as clusters of15 or 
more cells) were counted in 10 random fields. 
 
Proliferation assay by cell count  
Cells were seeded at a density of 10x104 cells/well on 6-well plates in 
complete growth medium and incubated over-night at 37°C in a humidified 
environment containing 5% CO2 to allow adherence. After described 
treatments, cells were trypsinized and stained with Trypan blue. The 
number of cells considered viable was counted in a Bürker 
haemocytometer within 5 minutes after staining. 
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Cell lysis and immunoblot 
Cells were extracted with 1% NP-40 lysis buffer (1% NP-40, 150 mM NaCl, 
50 mM Tris-HCl pH 8, 5 mM EDTA, 10 mM NaF, 10 mM Na4P2O7, 0.4 mM 
Na3VO4, 10 μg/ml leupeptin, 4 μg/ml pepstatin and 0.1 Unit/ml aprotinin). 
Cell lysates were centrifuged at 13.000 x g for 10 minutes and the 
supernatants were collected and assayed for protein concentration with the 
Bio-Rad protein assay method. Proteins were separated by SDS-PAGE 
under reducing conditions. Following SDS-PAGE, proteins were transferred 
to nitrocellulose, reacted with specific antibodies and then detected with 
peroxidase-conjugate secondary antibodies and chemioluminescent ECL 
reagent. Densitometric analysis was performed using the GS 250 Molecular 
Image (Bio-Rad).  
 
RNA isolation and Quantitative Real-Time PCR 
Total RNA was extracted from REN cells previously transfected with the 
plasmid, empty vector, siRNAs or nonspecific siRNA and, using the 
guanidiniumthyocianate method [21]. Starting from equal amounts of RNA, 
cDNA used as template for amplification in the Real Time PCR (5 μg), was 
synthesized by the reverse transcription reaction using RevertAidTM Minus 
First Strand cDNA Synthesis Kit from Fermentas-Thermo Scientific 
(Burlington, Ontario, CDN), using random hexamers as primers, according 
to the manufacturer’s instructions. As a PCR internal control, 18S was 
simultaneously amplified using the primers: Fw 5’-
AAACGGCTACCACATCCAAG-3’ and Rev 5’- 
CCTCCAATGGATCCTCGTTA-3’. The primers for Akt1 were Fw 5’-
GCTGGACGATAGCTTGGA-3’ and Rev 5’- GATGACAGATAGCTGGTG-
3’. The primers for Akt3 were Fw 5’-GCAAGTGGACGAGAATAAGTCTC-3’ 
and Rev 5’- ACAATGGTGGGCTCATGACTTCC- 3’.  These primers were 
designed to generate 383 (Akt1) and 329 (Akt3) bp products, respectively. 
Chapter 3 – Article 
65 
 
Primers for MTA1 were  Fw 5’- AGCTACGAGCAGCACAACGGG GT -3’, 
Rev 5’-CACGCTTGGTTTCCGAGGAT-3’and for CDH1 were Fw 5’-
TGGGCTGGACCGAGAGAGTT-3’ and Rev 5’- 
ATCTCCAGCCAGTTGGCAGT-3’. 
 
Statistical analysis 
Statistical evaluation of the differential analysis was performed by one way 
ANOVA and Student’s t-test. The threshold for statistical significance was 
set at P< 0.05.  
 
RESULTS 
 
AKT isoforms are differentially expressed in MPM tissues  
We recently published that MPM cells express AKT1 and -3 but not AKT2 
[16];  in the present study we better investigated AKT1 and -3 expression 
levels in different MPM tissues and cell lines representative of the three 
MPM histotypes: epitheliod, biphasic and sarcomatoid. Figure 1A and B 
report AKT1 and -3 mRNA expression levels evaluated in clinical surgical 
specimens from normal mesothelia and mesotheliomas with different 
histotype. As shown, tumor tissues express higher levels of AKTs mRNA 
compared to normal mesothelium, with the biphasic tumors expressing the 
highest levels of both AKT1 and -3 isoforms. Data reported in Figure 1C 
and D show a strong correspondence between results obtained in vivo 
(Figure 1A and B) and what observed in vitro when the expression of both 
AKTs was evaluated in different MPM derived cell lines. AKT1 and -3 
resulted increased in MPM derived cell lines compared to non-malignant 
mesothelial cells, with the highest expression of both isoforms in the 
MSTO-211H cell line established from a tumor with biphasic histotype.  
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Based on these results, we decided to mainly use this cell line as a model 
to perform further in vitro experiments.  
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Figure 1. AKT isoforms are differentially expressed in MPM cell lines and tissues 
A, B. Bar graphs representative of AKT1 and AKT3/18S  mRNA ratio evaluated by RT-
PCR in surgical specimens of tumors with different histotype from mesothelioma patients 
and in normal mesothelium.  C, D. Bar graphs representative of AKT1 and AKT3/18S 
mRNA ratio in normal mesothelial cells and in different mesothelioma cell lines 
representative of the three hystotypes.  Data, shown as fold induction versus benign, are 
means ± S.D. of three independent experiments. 
 
AKTs inhibition affects MPM cell viability and enhances cisplatin 
induced apoptosis  
Figure 2B shows that MSTO-211H cells constitutively express 
phosphorylated AKTs. We demonstrated that 24 hours treatment of MSTO-
211H cells with MK2206, an highly selective inhibitor of AKT1, -2 and -3, 
markedly decreased AKTs phosphorylation (Figure 2B) and significantly 
compromised cell viability (Figure 2A). As it has been described a role of 
AKT in cisplatin resistance, we tested the effect of AKTs inhibition in 
response of MSTO-211H cells to this chemotherapic. Concomitant 
treatment of cells with MK2206 and cisplatin resulted in enhanced cisplatin 
induced apoptotic cell death as evidenced by cell count (Figure 2A) and 
increased PARP1 cleavage (Figure 2B). Thus, we explored the effect on 
cell viability and cisplatin response of specific knockdown of AKT1 and -3 
isoforms by specific siRNA. Non-specific siRNAs were used as control. As 
shown in Figure 1C, down-regulation of both AKT1 and -3 had a significant 
impact on MSTO-211H cells viability in monolayer culture, although the 
reduction due to the loss of AKT 3was more significant. Cisplatin treatment 
resulted in increased apoptotic cell death in both AKT1 and -3siRNA 
transfected cells compared with the non-specific control siRNAs (Figure 
1C), indicating that both activated AKTs are essential for cell survival and 
play a role in response to chemotherapy. The AKT1 and -3 silencing 
efficiency was confirmed by mRNA (Figure 2E) and protein analysis (Figure 
2F).  
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Figure 2. AKTs inhibition induces MPM cell death and enhances cisplatin induced 
apoptosis  
A. The effect of MK2206 on the MSTO-211H cell viability was tested at 24 hours in the 
absence or in the presence of 25 µM cisplatin. Points, means ± SD of three individual 
measurements. B. Representative Western blot analysis that documents PARP1 cleavage 
and AKTs phosphorylation in response to 24 hours treatment with MK2206 ± 25 µM 
cisplatin. C. MSTO-211H cell viability was evaluated after 72 hours of transfection with 
specific siRNA for AKT1 and AKT3 in the absence or in the presence during the last 24 
hours of 25 µM cisplatin. Points, means ± SD of three individual measurements. D. 
Representative Western blot analysis that documents PARP1 cleavage in cells silenced for 
AKT1 or -3 ± 24 hours of 25 µM cisplatin. E, F. Representative quantitative RT-PCR and 
Western blot analysis that confirm AKT1 and -3 silencing in MSTO-211H cells. 
 
 
AKT1 silencing mediates MPM cell shape changes and affects 
clonogenic growth 
As described, down-regulation of both AKT1 and -3 had a significant impact 
on MSTO-211H cells viability in monolayer culture but, interestingly, only 
AKT1 down-regulation caused a dramatic change in MSTO-211H cell 
shape. Knockdown of AKT1 reverted the MSTO-211H spindle-shaped cell 
morphology to a more epithelial one (Figure3A-b); conversely AKT3 down-
regulation exaggerated the spindle-shaped phenotype (Figure3A-c). By 
AKT1 and -3 double silencing experiments, we demonstrated that the 
epithelial phenotype, induced by AKT1 down-regulation, was maintained 
both in the presence and in the absence of expressed AKT3 (Figure 3A-d), 
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indicating that this change is due to reduced expression of the AKT1 
isoform and does not dependent from AKT3. Consistently with the observed 
change in cell morphology, an increase in CDH1 (E-Cadherin coding gene) 
expression was observed in AKT1 silenced cells and again this occurred 
independently from AKT3 expressed levels (Figure 3B). We further 
examined AKTs induced modifications by employing a Matrigel-overlay 
model. The silencing of AKT1in MSTO-211H cells associated with reduced 
adhesion and cells that remained clumped together as compared to the 
cells treated with control siRNAs (Figure 3C-b) while cells silenced for 
AKT3 formed structures with more invasive protrusions (Figure 3C-d). 
Finally, AKT1down-regulation significantly compromised the capability of 
MSTO-211H cells to form colonies in soft agar (Figure 3D-b, d) while, in 
contrast, AKT3 down-regulation did not result in significant variations in the 
number of colonies which, however, appeared larger if compared to 
controls (Figure 3D-c). These results support a role for AKT1 in promoting 
EMT (epithelial to mesenchymal transition) and invasiveness of MPM cells. 
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Figure 3. AKT1 silencing mediates MPM cell shape changes and affects clonogenic 
growth 
A. Phase-contrast images of MSTO-211H cells after 72 hours of transfection with non-
specific siRNA (a), AKT1 (b), AKT3 (c) or both AKT1 and -3 (d) grown as monolayer. B. 
Representative quantitative RT-PCR that documents CDH1 and MTA expression in cells 
transfected with non-specific siRNA, AKT1, AKT3 or both AKT1 and -3. C. Representative 
phase-contrast images of MSTO-211H cells transfected with  non-specific siRNA (a), AKT1 
(b), AKT3 (c) or both AKT1 and -3 (d) grown for 1 week on Matrigel. D. Phase-contrast 
images of MSTO-211H cells transfected with  non-specific siRNA (a), AKT1 (b), AKT3 (c) 
or both AKT1 and -3 (d) grown for 1 week in soft agar. Total soft agar colony counts for 
silenced and non-silenced MSTO-211H cells were done in three independent experiments 
microscopically visualizing individual colonies (clusters of 15 or more cells) in 10 random 
microscopic fields. Columns represent the fold increase of the mean number of colonies in 
10 fields; bars, SD; *p,0.05. Representative of three separate experiments.  
 
AKT1 kinase inhibition or protein loss exerts different effects in MPM 
cells 
To discriminate if the observed phenotype transition was due to the loss of 
AKT1protein or to the loss of its activity, we treated MSTO-211H cells with 
MK2206. As show in Figure 4A the morphology in monolayer culture did not 
change in response to treatment with MK2206, indicating that the observed 
induction of the less invasive epithelial phenotype depends on the physical 
presence of AKT1 rather than by its activation status. Figure 4B shows a 
representative Western blot analysis that confirms the inhibition of AKT 
phosphorylation upon MK2206 treatment. RT-PCR analysis shown Figure 
4C confirms that neither CDH1 nor AKT1 expression changes in MK2206 
treated cells. To reinforce our data, we over-expressed AKT1 by transient 
transfection in the epithelioid MPM derived REN cells. Western blot shown 
in Figure 4E confirms the induction in AKT1 expression and activation in 
transfected cells. As shown in Figure 4D transfected cells acquired a more 
spindle phenotype and in accordance, as shown in Figure 4F, the 
expression of the CDH1 gene was reduced. 
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Figure 4. Different effects exerted by AKT1 kinase inhibition or protein loss in MPM 
cells 
A. Phase-contrast images of MSTO-211H cells treated with MK2206 grown as monolayer. 
B. Representative Western blot analysis that documents AKT expression and 
phosphorylation in control and MK2206 treated cells. C. Representative quantitative RT-
PCR that documents AKT1 and CDH1 expression in control and MK2206 treated cells. D. 
Phase-contrast images of REN cells transfected with an AKT1-HA expression vector 
grown as monolayer. E. Representative Western blot analysis that documents AKT 
expression and phosphorylation in control and AKT1 transfected cells, tubulin was used as 
loading control. C. Representative quantitative RT-PCR that documents AKT1 and CDH1 
expression compared to 18S, in control and AKT1 transfected cells.  
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DISCUSSION 
 
AKTs are activated in human cancer and play a critical role in tumor 
pathogenesis, via effects on metabolism, survival, and proliferation [22]. 
The role of AKTs in cell migration and metastases is less clear because of 
conflicting studies suggesting either positive or negative regulatory roles. In 
studies in which roles for AKT1 and AKT2 in cell motility have been 
reported, distinct and, in some cases, opposing functions for the two 
isoforms are  observed. Differences seem to depend mainly on the cell type 
being studied. For example, in fibroblasts and endothelial cell, AKT1 has 
been found to promote invasion while AKT2 attenuates it [22, 23]. In PC-3 
cells, AKT2 ablation stimulates and AKT1 ablation inhibits cell migration. 
Conversely, previous studies have found that AKT2 stimulates the motility 
of breast and ovarian cancer cells, AKT1 actually inhibits the motility of 
these cells [25]. In the present study, we show that AKT1 and -3 are 
expressed and active in MPM cells. Treatment of MPM cells with the pan-
AKTs inhibitor MK2206 alone caused a significant reduction in cell viability. 
As a role of AKT inhibition in sensitizing cells to cisplatin treatment has 
been described, we tested the combined treatment with MK2206 and 
cisplatin in MSTO-211H cells. We observed that the concomitant treatment 
with MK2206 resulted in enhanced cisplatin induced apoptotic cell death.  
Therefore, we investigated the isoform-specific functions of AKT1 and -3 in 
MSTO-211H cells by the use of specific siRNA. Knockdown of AKT1 or-3 
reduced cell viability and potentiated apoptotic cell death when cisplatin 
treatment was added. Further investigations are needed to delucidate the 
mechanisms by which the AKT isoforms promote cell survival in MSTO-
211H cells, but it seems that even though both AKT1 and -3 play essential 
roles in this cell type survival, they likely act through different mechanisms.  
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Importantly, we observed that AKT1 down-regulation caused in these cells 
a reversion versus a more epithelial phenotype when cultured in monolayer, 
a reduction in spreading on Matrigel and a near complete inhibition of the 
growth in 3D cultures in soft agar. In contrast, AKT3 down-regulation didn’t 
influence these processes. Our studies highlight the isoform-specific nature 
of these effects and establish a role for endogenous AKT1 protein in 
affecting cell invasion.  
The specific mechanisms responsible for the distinct roles of AKT1 and -3 
are not known; however, there are few explanations extrapolated from 
previously published studies. Differential subcellular localization or binding 
partners may determine isoform-specific functions. The balance between 
AKT isoforms activation downstream of growth factor receptors may 
influence the invasive or metastatic potential of tumors or tumor cell lines. 
The consequences of isoform-specific inhibition need to be carefully 
evaluated in different cellular contexts. 
Efforts are underway to develop pan- or isoform-specific AKT inhibitors as 
cancer therapeutics [26-28]. By the use of a specific inhibitor of AKTs 
activation, we demonstrated that it is the physical presence and not the 
activation status of AKT1 that influence all of the effects observed in 
culture. This could be in part explained by the fact that the drug-inhibited 
protein may lack a certain activity but may still interact with some binding 
partners or assemble into macromolecular complexes. 
In conclusion, we have demonstrated that AKT1 and -3 comparably 
contribute to cell survival but have different impact on cell invasion and 
consideration of this may aid in the development of targeted strategies for 
specific AKT isoforms inhibition in MPM therapy. 
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Chapter 4  
 
HSC70 (Heat Shock Cognate Protein-70) and AKT interaction 
 
INTRODUCTION 
Chaperone proteins, acting in different cell compartments, play an 
important role in protein homeostasis, and are involved in different cellular 
processes. 
The majority of the HSP70 proteins are mainly located in the cytosol and in 
the nucleus (HSPA1A/B, HSPA1L, HSPA2, HSPA6 and HSPA8), while two 
members remain restricted to mitochondria (HSPA9) or endoplasmic 
reticulum (HSPA5). HSP70 family members present high sequence identity 
(around 80% of their sequence) and similar structure (1). 
Among HSP70 chaperones, one of the most abundantly and ubiquitously 
expressed across all tissues protein is HSPA8/HSC70. HSPA8 (also known 
as HSC70, HSC71, HSP71, or HSP73) is known as the constitutive 
member of the cytosolic HSP70 family and plays a central role in many 
cellular processes; it presents sequence identity of 85% to HSPA1A and 
represents up to 1% of the total cellular protein content in transformed cells 
(2). The main processes that have been related to HSPA8 (often in 
association with co-chaperones), are represented by clathrin-mediated 
endocytosis, protein folding and the ubiquitin-proteasome mediated 
degradation. 
During the first process, binding of a ligand to a transmembrane receptor 
induces the formation of a cavity. Clathrin binds the nascent pit in order to 
induce the formation of regular endosomes; then clathrin is dissociated 
from endosomes through an HSPA8-dependent mechanism.  
Moreover, an in vivo study on protein folding revealed that HSPA8 binds a 
wide variety of polypeptides of size larger than 20 kDa, representing 20% of 
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newly translated proteins: also, protein folding seems to occur in a 
protected environment formed by chaperones and co-chaperones (3). 
HSPA8 is composed of 2 domains: the N-terminal Nucleotide Binding 
Domain (NBD) and the C-terminal Substrate Binding Domain (SBD). The 
NBD is composed of 2 lobes I and II, divided in 2 subdomains Ia-Ib and II-
IIb; the nucleotide-binding pocket is also composed of two subdomains, a 
15-kDa β-sandwich binding the substrate and a 10-kDa R-helix that closes 
the binding site and increases the affinity for the peptide (4, 5). HSPA8 
binds to small hydrophobic stretches of nascent or partially unfolded 
proteins in an ADP/ATP-dependent manner. HSPA8 firstly binds client 
proteins in a low affinity; after this binding and with the help of accessory 
proteins from the HSP40 family, it hydrolyzes ATP into ADP, adopting a 
high affinity; through the action of so-called nucleotide exchange factors 
(NEFs), it reverts to its ATP-state thus releasing its substrate peptide. The 
cycling between these two states (fast-exchange to low-exchange ATP) 
enables HSPA8 to exert its chaperone activities that rely on conformational 
changes of the protein upon nucleotide and clients binding.  
HSPA8 exerts a key role in ubiquitin mediated protein degradation: the 
ubiquitin-proteasome degradation system consists in adding multi-ubiquitin 
chains to a protein substrate, as a signal for targeting and degradation by 
the proteasome proteolytic complex: in this system, the C-terminus of the 
HSPA8-interacting protein (CHIP) bridges HSPA8 to the proteasome by 
interacting with the chaperone and acts as an E3 ubiquitin ligase, coupling 
ubiquitin chains to the chaperone substrate (6). 
Furthermore, the involvement of HSPA8 in protein import into cellular 
compartments has been broadly studied. The chaperone is able to shuttle 
between the nucleus and the cytoplasm in an ATP-dependent manner and 
this property allows HSPA8 to import different cytoplasmic proteins into the 
nucleus, while other studies correlate the role of HSPA8 in cellular transport 
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of organelles along microtubules. As shown by Nirdé et al., HSPA8 is also 
detected in the extracellular space: it may derive from dying cells, but it can 
also be actively released from viable cells, free or associated with 
exosomes; in this case, extracellular HSPA8 may inhibit tumor cell growth 
and affect cell viability (7). 
In literature, it has been described the role of SIRT1 (Sirtuin1), a NAD 
dependent deacetylases, in the modulation of AKT activation and a role of 
PARP1 ((Poly(ADP ribose)polymerase 1) as a gatekeeper for SIRT1 
activity by limiting NAD+ availability (8). 
SIRT1 inhibition or silencing results in a more evident AKT acetylation and 
reduced phosphorylation (9). Previously our group has demonstrated that in 
basal conditions AKT was in part acetylated and in part phosphorylated, 
while on the contrary, upon PARP1 inhibition, AKT becomes highly 
phosphorylated and completely de-acetylated. Moreover, AKT acetylation, 
upon SIRT1 inhibition or silencing, results in the association of different 
acetylated proteins to AKT. We identified these interactors by MALDI-TOF 
analysis. In this work, among all the interactors, we decided to investigate 
HSC70. We better defined its relationship with AKT and explored its 
involvement in AKT activation and in EGF-signaling in MPM cells. 
 
MATERIALS AND METHODS 
 
Reagents and antibodies 
EGF (Sigma-Aldrich) was dissolved, stored at -20° and used at final 
concentration of 10 ng/ml; EX527 (Selleckchem, Houston, TX) was 
dissolved in DMSO, stored at -20° and used at final concentration of 10 
ug/ml. Nitrocellulose membranes and protein assay kits were from Bio-Rad 
(Hercules, CA). The EGFR, HSC70, AKT and phospho-AKT antibodies 
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The 
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phospho-ERK antibody was purchased from Cell Signaling Technology 
(Beverly, MA).  Anti-mouse and anti-rabbit IgG peroxidase conjugated 
antibodies were from Sigma-Aldrich (St Louis, MO). 
 
Cell Culture, treatments and transfection 
The MPM derived REN cell line, used as the principal experimental model 
in the current study, was kindly provided by Dr. S.M. Albelda (University of 
Pennsylvania, Philadelphia, PA); cells were cultured in RPMI 1640 medium 
supplemented with 10% foetal bovine serum (FBS), 100 units/ml penicillin, 
100 units/ml streptomycin, and 2mM glutamine, at 37°C in a 5% CO2-
humidified atmosphere. For HSPA8 silencing in REN cells, we used specific 
siRNA by QIAGEN (Hilden, Germany) and Lipofectamine® transfection 
reagent (Invitrogen, as described by the manufacturer).  
 
Cell proliferation assay  
For cell proliferation assays, cells were seeded at a density of 10x10
4
 in 51 
mm petri dishes in complete growth medium and incubated overnight at 
37°C in a humidified environment containing 5% CO2. After 24 hours, cells 
were transfected with HSC70 specific or non-specific siRNA. Human 
recombinant EGF was added to medium supplemented with 2% of FBS after 
4h of transfection and cells were allowed to grow for 24, 48 and 72 hours, ; 
at the end of treatment, viable cells were counted in a Burker 
haemocytometer. 
 
Cell lysis, immunoprecipitation and Western Blot  
REN cells were seeded at a density of 10x104 cells in 51 mm petri dishes in 
complete growth medium and incubated overnight at 37°C in a humidified 
environment containing 5% CO2. After 24 hours, cells were transfected with 
HSC70specific siRNA. After 72 hours of transfection, cells treated with EGF 
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(10ng/ml) for 5, 10 and 15 minutes. Cells were then lysed and proteins 
were analyzed by Western Blot.  
Cells were lysed in NP40-lysis buffer [50mM Tris-HCl (pH 8.0), 150mM 
NaCl, 1% NP40, 5mM EDTA, 10 mM NaF, 10mM Na4P2O7, 0.4 mM 
Na3VO4, 10 μg/ml leupeptin, 4 μg/ml pepstatin and 0.1 Unit/ml aprotinin]. 
Lysates were centrifuged at 13.000 x g for 10 minutes and the supernatants 
were collected and assayed for protein concentration using the Bradford 
protein assay reagent (Bio-Rad). Proteins were separated by gel 
electrophoresis on 8% polyacrylamide gels, transferred to nitrocellulose 
membranes and detected by immunoblotting using an enhanced 
chemiluminescence system (Amersham Pharmacia Biotech, Uppsala, 
Sweden). For immunoprecipitation experiments, 2 mg of proteins were 
incubated with the antibody for 1 hour at 4° C in the presence of 40 μl 
protein A-Sepharose beads (50%) per 1 ml. The beads were washed three 
times with 1 ml of PBS, 0.5% Triton X-100 and once with 1 ml of PBS, 0.5% 
Triton X-100, 0.1% SDS and the immunoprecipitates were eluted by boiling 
the beads in 2X Laemmli sample buffer for 5 minutes and loaded on SDS-
PAGE. For interactors identification, gel was stained with blue Comassie, 
the evidenced bands were cut and proteins analyzed through MALDI-TOF 
analysis. 
 
RNA isolation and RT-PCR  
Total RNA was extracted from REN cells transfected with HSC70 or 
nonspecific siRNAs with the Trizol Reagent (Life Technologies, Inc.), 
according to the manufacturer’s protocol. To obtain cDNA, reverse-
transcription reaction was performed starting from 5 mg of RNA extracted, 
using RevertAidTM Minus First Strand cDNA Synthesis Kit from Thermo 
Scientific (Burlington, Ontario), as manufacturer’s instructions. Primers 
were synthesized by MWG. The primers for 18s rRNA(housekeeping gene) 
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were: 5’-AAACGGCTACCACATCCAAG-3’ (sense) and 5’-
CCTCCAATGGATCCTCGTTA-3’ (antisense) and for CDH1 were: 5’-
TGGGCTGGACCGAGAGAGTT-3’ (sense) and 5’- 
ATCTCCAGCCAGTTGGCAGT-3’ (antisense). RT-PCR reactions were 
performed using 2xPCR Fusion Flash Master Mix from Thermo Scientific 
with the following programs: (18s) denaturation at 94°C for 3 minutes, 
followed by 30 cycles at 94°C for 30 seconds, 57°C for 5 seconds and 72°C 
for 3 seconds, with a final extension at 72°C for 1 minute; (CDH1) 
denaturation at 94°C for 3 minutes, followed by 35 cycles at 94°C for 30 
seconds, 55°C for 5 seconds and 72°C for 30 seconds, with a final 
extension at 72°C for 1 minute. The PCR products expected (respectively, 
155 Bp and 612 Bp) were electrophoresed on a 1% agarose gel and 
visualized with ethidium bromide. 
 
RESULTS 
 
Sirt1 inhibition induces AKT acetylation and association with different 
proteins 
The role of SIRT1 in the modulation of AKT activation has been clearly 
described. SIRT1 activates AKT by enhancing its binding to PIP3 and 
thereby increasing its membrane localization and phosphorylation; 
moreover, two conserved lysine residues in the PH domain of AKT are 
subject to acetylation and their SIRT1-dependent deacetylation is 
necessary to allow AKT binding to PIP3 (10). Recent data published by our 
group demonstrate the role of SIRT1 in the control of the balancing 
between acetylation and phosphorylation of AKT upon PARP1 inhibition, in 
MPM cells: in basal conditions AKT is in part acetylated and in part 
phosphorylated, while inhibition (or silencing) of SIRT1 resulted in a more 
evident AKT acetylation (Fig. 1A) (9). REN cells were treated with the 
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SIRT1 inhibitor EX527 at the concentration of 10 µg/ml for 24 hours, AKT 
was immunoprecipitated and samples were loaded on SDS-PAGE and 
subsequently stained with blue Comassie. Bands representing different 
AKT interactors were excised from the gel and then identified through 
MALDI-TOF analysis. Among these proteins we focused further studies on 
the Heat shock cognate protein 70 (HSC70) (Fig. 1B). 
 
 
   
 
 
 
 
  
                                                       
 
Fig. 1 - Upon SIRT1 inhibition AKT is more acetylated and associates other 
acetylated proteins.  
A. A brief scheme of balancing between acetylation and phosphorylation of AKT (Pinton et 
al, 2013). B. REN cells were treated with 10uM EX527 for 24h. Immunoprecipitation of 
total AKT was performed and different bands corresponding to interactors were highlighted 
with Comassie staining of SDS-PAGE and finally identified through MALDI-TOF analysis. 
P 
P 
A 
B 
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HSC70 knock-down resulted in morphological changes and decreased 
cell viability 
HSC70 is considered an essential housekeeping gene, and HSC70-
knockout mice are embryonically lethal as a result of the pivotal role of 
HSC70 in cell survival. In literature it has been reported that transfection 
with HSC70 siRNA results in massive cell death. As a consequence of 
HSC70 inhibition in REN cells, we observed a significant change in cell 
morphology from an epithelial, to a spindle shape (Fig. 2A). Morphological 
changes were associated with a decrease in E-Cadherin expression as 
documented by the RT-PCR expression analysis of CDH1 gene, shown in 
(Fig. 2B). Moreover, according to previous studies, we observed an 
important decrease in cell number upon HSC70 silencing (Fig. 2C). 
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Fig. 2 - Morphological changes and viability of mesothelioma cells after HSC70 
silencing. A. Phase-contrast images of REN cells after 72h from transfection with non-
specific (c) or HSC70 siRNA. Silenced cells result reduced in number and display a more 
spindle phenotype. B. RT-PCR documents the expression of CDH1 in control and HSC70 
silenced cells. 18S rRNA was used as housekeeping gene. C. Bar graphs documents cells 
viability reduction in HSC70 silenced cells. Bars represent means ±SD of three 
independent measurements. 
 
HSC70 knock-down affects AKT activation in REN Cells 
We examined the effects of HSC70 silencing on basal AKT 
phosphorylation. Western Blot analysis, shown in Fig. 3A, documents that 
AKT phosphorylation was abolished in HSC70-silenced cells; while the total 
amount of AKT resulted increased, and in particular, AKT1 is the main 
isoform modulated in Hsc70 silenced cells  (Fig. 4).  
 
Fig. 3 – HSC70 silencing reduces AKT phosphorylation.  
A. Representative Western blot analysis that documents the inhibition of AKT 
phosphorylation and the total amount of AKT protein in wild type and HSC70 silenced 
cells.  
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Fig. 4 – Loss of HSC70 resulted in AKT1 accumulation.  
A. Representative Western blot analysis of AKT1 and AKT3 isoform expression in wild 
type and HSC70 silenced cells.  
 
 
HSC70 silencing reduces EGFR phosphorylation and expression and 
affects EGF-induced proliferation in REN cells 
REN cells express high levels of EGFR, so we explored the effects of 
HSC70 silencing on its activation and signaling. After 72 hours of 
transfection, cells were starved 1 hour and treated with 10ng/ml EGF for 5, 
10 and 15 minutes. Western blot analysis of lysates from REN cells 
revealed that the level of phosphorylation reached a maximum after 10 
minutes of treatment; however, this was significantly inhibited in cells 
transfected with siRNA–HSC70 (data not shown). In particular, at 10 
minutes of EGFR treatment, we observed that EGFR phosphorylation 
diminished such as the total expression of the receptor, suggesting a direct 
involvement of HSC70 in EGFR signaling pathway and recycle (Fig. 5A). 
AKT phosphorylation was compromised even in the presence of EGF, while 
ERK 1/2 phosphorylation was not affected (Fig. 5A). After assessing the 
relationship between HSC70 and EGFR activation, we explored if HSC70 
could play a role in EGF-dependent cell growth. Transfected cells were 
treated with EGF (10ng/ml) in medium supplemented with 2% FBS for 
72hours. As previously described, HSC70 silencing significantly 
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compromised REN cells viability both in basal and EGF stimulated 
conditions (Fig.5B). 
 
 
 
 
                        B 
 
 
Fig. 5 – HSC70 silencing affects EGFR signaling.  
A. Representative Western blot analysis that documents phosphorylation and expression 
of EGFR in wild type and HSC70 silenced cells, treated or not with 10 ng EGF for 24 
hours. B. Cell viability of wild type and HSC70 silenced cells treated 24, 48 and 72 hours 
with 10 ng EGF. Bars represent means ±SD of three independent measurements. 
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DISCUSSION 
In the present study, we examined the role of HSC70 in REN cells in basal 
conditions and in the response to EGF treatment. HSC70 is a chaperone 
protein constitutively expressed in cells in normal conditions and is involved 
in protein folding; if cells are exposed to stress, the expression of HSC70 
changes and often increases, to prevent mis-folding and de-regulation of 
proteins. As reported in many papers, tumour cells express high levels of 
HSC70. Silencing of HSC70 in REN cells, an epithelioid mesothelioma 
derived cell line, caused a strong decrease in cell viability that was reduced 
up to less than 50 % compared to the untreated cells.  
Moreover, morphological changes observed in silenced cells (cells 
assumed a spindle shape) suggest the importance of this chaperone in the 
modulation of proteins involved in the organization of the cytoskeleton. In 
summary, our results show that a transient HSC70 knockdown decreased 
AKT phosphorylation; on the contrary, the total amount of protein was 
increased indicating that AKT was accumulated in an inactive state, and 
that HSC70 silencing prevented its phosphorylation, but probably acted on 
its stability. Furthermore, we demonstrated that AKT isoforms has different 
relationship with this chaperone protein: in fact in HSC70 silenced cells, 
AKT1 was increased while AKT3 was markedly reduced.  
We evidenced in silenced cells a reduction of E-Cadherin mRNA and these 
data are consistent with the morphological changes and the observed 
increase of AKT1. Finally, EGF did not contrast the effects of HSC70 
silencing, in terms of AKT activation, because also EGFR expression and 
signaling were affected.  
Taken together, these data suggest that HSC70 acts modulating AKT 
stability and activity; AKT contributes to cell survival and AKT blockade by 
HSC70 knock-down may trigger cell death; the absence (or the alteration) 
Chapter 4 – Unpublished Results 
93 
 
of HSC70 led to an increase and accumulation of AKT, in particular of 
AKT1 isoform.  
In conclusion, this study suggests that HSC70 is strictly involved in AKT 
stability, and better understanding this inter-relationship, may be useful to 
provide new insights for therapeutic strategies. 
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Chapter 5 
 
Conclusions 
 
Malignant Mesothelioma (MM) is an asbestos-related highly aggressive 
cancer arising from the mesothelium that lines pleura, peritoneum or 
pericardium. It is characterized by a long latency period, poor prognosis 
and high chemo-resistance and its incidence, although the use of asbestos 
has been banned in many countries, has been predicted to increase 
dramatically worldwide during the next two decades. The PI3K/AKT 
signaling pathway is one of the major pathways involved in carcinogenesis 
and tumor progression; it is aberrantly active in several human cancer and 
it has been described to play an important role in human malignant pleural 
mesothelioma (MPM). 
We firstly demonstrated that MPM cell lines express only two AKT isoforms, 
AKT1 and AKT3 and, differently from lung adenocarcinoma cells, they lack 
of AKT2; the levels of the two expressed isoforms resulted increased if 
compared with normal mesothelial cells and  was related to tumor 
histotype.  
Based on these data, in our first work we better characterized AKT isoforms 
expression and function in MPM cells.  
AKT1 and -3 resulted increased in MPM derived cell lines and in particular 
the highest expression of both isoforms was observed in the MSTO-211H 
cell line established from a tumor with biphasic histotype. The same 
distribution was observed in vivo in freshly prepared surgical specimens. 
To confirm the importance of the AKT pathway in this tumor, we 
investigated the effects of the MK2206 inhibitor on our cell model and 
evidenced both a significant reduction in AKTs phosphorylation and in cell 
viability. As the importance of AKT in mediating cisplatin resistance has 
been described, we tested the effects of the combined treatment with 
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cisplatin and MK2206. AKT inhibition resulted in enhanced cisplatin 
sensitivity with increased apoptotic cell death, as shown by PARP-1 
cleavage.  
Moreover, in order to define the specific role of each AKT isoform we 
evaluated the effect of specific silencing of AKT1 and -3. The specific 
knock-down of AKT1 or -3 had a strong effect on cell growth in monolayer, 
more evident for AKT3, while in terms of cisplatin sensitivity, both silencing 
of AKT1 or -3 reduced cell viability and increased apoptotic cell death, 
suggesting the essential, but different roles of these two isoforms. 
The role of different AKTs in cell migration and metastases has been 
described in distinct tumors, but it remains to be better clarified, as different 
and conflicting studies suggest either positive or negative regulatory roles 
of each AKT isoform. As previously described, MSTO-211H cells are 
derived from a biphasic histotype, show a spindle morphology and express 
high level of both AKT1 and -3.  
AKT1 silencing resulted in a reversion versus a more epithelial phenotype 
when MSTO-211H cells were cultured in monolayer, while upon AKT3 
down-regulation the spindle morphology was stressed. 
According to the evidenced morphological changes, AKT1 silenced cells 
showed an increase in E-Cadherin expression. Double silencing 
experiments underlined that this change was maintained both in the 
presence or in the absence of AKT3 expression, indicating that it strictly 
depends from AKT1 expression.  
As described in different works, E-Cadherin is considered a marker of 
epithelial-mesemchymal transition and its increase or decrease 
corresponds to cell capability of invasion/migration. We explored if the 
silencing of AKT1 could affect cell adhesion and 3D cultures: AKT1-
silenced cells resulted in a reduction of cell spreading on Matrigel and in a 
complete inhibition of colony growth in soft agar. Conversely, AKT3 knock-
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down did not influence these processes: we didn’t observe significant 
variations in the number of colonies which appeared even larger if 
compared to the controls. Taken together, all these results led us to 
establish a primary role for the endogenous AKT1 protein in affecting 
anchorage independent cell growth and underline the isoform-specific 
nature of this effect.  
Again, we wanted to discriminate if the observed phenotype transition was 
a consequence of AKT1 loss-of-protein or was dependent by the loss of its 
activity: AKT inhibition with MK2206 did not cause the morphological 
changes observed in silenced cells. Conversely when AKT1 was 
overexpressed in epithelioid REN cells induced phenotypic changes 
towards  more spindle-shaped  cells. 
Taken together all these data demonstrate that AKT1 and -3 contribute to 
cell survival, evidence distinct roles on MPM cell adhesion and highlighting 
that the observed effects mainly depends on the physical presence (and not 
on the activation status) of AKT1.  
Drug-inhibited AKT1, in fact, lack of a specific kinase activity but could  still 
retain interactions with other binding partners or assemble into 
macromolecular complexes. 
As previously described in our laboratory, in MPM cells, AKT is in part 
phosphorylated and in part acetylated in basal conditions, while upon Sirt1 
inhibition it becomes more acetylated and associates with different proteins, 
as shown by immunoprecipitation experiments. 
Based on this evidence, the last aim of my studies was to explore the roles 
of these associated proteins and among those identified by MALDI-TOF 
analysis, we focused on HSC70, a chaperone protein constitutively 
expressed across tissues and cell types.  
HSC70 is considered an essential housekeeping gene and in literature it 
has been reported that its silencing results in massive cell death.  
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We reported that silencing of HSC70 leads to a strong reduction in cell 
viability and in visible morphological changes, associated with a decrease 
in E-Cadherin expression. We further investigated the relationship between 
HSC70 and AKTs and the effects of its knock-down on AKTs activation. 
Our data indicated that AKT1 phosphorylation  was affected by silencing of 
HSC70, while the total protein amount resulted increased and interestingly 
our results demonstrated that EGF stimulation was not able to rescue AKT 
activation and that EGFR phosphorylation itself diminished. HSC70 
silencing significantly compromised viability of MPM cells both in basal and 
EGF stimulated conditions. 
In conclusion, these data suggest that HSC70 acts modulating AKT stability 
and activity; better understanding of this inter-relationship, may be useful to 
further explain the role of this protein in MPM and also provide new insights 
for novel therapeutic strategies. 
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